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Abbreviations 
 
AD – Alzheimer’s Disease 
SAD – Sporadic Alzheimer’s disease 
ADAD – Autosomal Dominant Alzheimer’s disease 
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II 
Abstract 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease ranging from an 
asymptomatic preclinical phase to dementia. A small subset (less than 5%) of AD patients, 
starting at an early age (from 30 to 65 years old), was found mainly caused by the genetic 
mutation which is autosomal dominant AD (ADAD). Even though ADAD only accounts for a 
small proportion of AD, because of similar pathological and clinical features, it is critical to 
better understand the pathophysiology in the preclinical stage of sporadic AD (SAD).  
Decades before the dementia onset, the earliest changes have already occurred in the brain 
even though the cognitive function is still normal. Such a long phase of gradual brain changes 
offers the opportunity to detect the disease in the preclinical phase. However, due to the subtle 
degree of the brain changes and the unclear etiology in the early stage of AD, it is a 
challenging task to establish markers for the prediction of the development of dementia. 
Moreover, subjects in the early-stage SAD may have additional brain changes that are 
unrelated to AD pathology. To address this problem, we proposed a machine learning model 
based on patients with ADAD, i.e. pure genetically caused AD which not accompanied by 
aging-related co-pathologies due to the early disease onset that can start in the third decade of 
life.  
Previous studies in both ADAD and SAD have shown that markers of pathological brain 
changes including brain atrophy, cerebral glucose hypometabolism, as well as amyloid-beta 
(Ab) and pathologic tau protein are altered in AD (Clifford R. Jack et al., 2010; Dickerson 
and Wolk, 2013). Recent guidelines for early diagnosis of AD recommended using a 
combination of neuroimaging, CSF biomarkers and neuropsychological tests for aiding the 
diagnosis of AD (Sperling et al., 2011). In the present work, we established a classification 
model for the early detection of AD in the predementia phase using machine learning. First, 
we employed the Naïve Bayes algorithm for classification and information gain method for 
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feature selection. Features were derived from neuroimaging (MRI, FDG-PET), CSF 
biomarkers, and neuropsychological tests. First, we trained the classification model based on 
the ADAD sample and subsequently validated the best prediction model with optimal 
combinations of multi-modalities in a larger independently recruited sample of subjects with 
SAD (ADNI dataset).  
We found high accuracy for distinguishing HC vs. AD and MCI converters vs. non-
converters. Generally, combining multiple modalities, the classification model yielded a 
better result than the single-modality model. Particularly, the classification for MCI 
converters versus non-converters in SAD showed the best result when using FDG-PET, 
neuropsychological and CSF data with AUC of 89.12% (sensitivity = 82.79%, specificity = 
82.42%) which is above the clinical relevant accuracy. In summary, the machine learning 
model established in DIAN achieved predictive accuracy to distinguish the converters versus 
non-converters in the early stage of SAD. Moreover, the current study provides good 
interpretability to understand SAD through ADAD. 
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Zusammenfassung 
 
Die Alzheimer Krankheit (AK) ist eine fortschreitende neurodegenerative Erkrankung, die 
ausgehend von einer asymptomatischen präklinischen Phase in eine Demenz mündet.  Schon 
Jahrzehnte bevor klinische Symptome sichtbar werden, zeigen sich pathologische 
Veränderungen im Gehirn der Betroffenen. Diese lange prodromale Phase bietet die 
Möglichkeit die Krankheit frühzeitig zu erkennen und eine Therapie einzuleiten. Allerdings 
sind die ersten Hirnveränderungen oft marginal und auch wegen der unklaren Ätiologie ist es 
im Frühstadium der AK schwierig eine gute Vorhersage darüber zu treffen, welcher Patient in 
das nächste Krankheitsstadium fortschreiten wird. Zusätzlich leiden gerade ältere Patienten 
mit einer sporadischen AK, deren Risiko nach der 6. Lebensdekade start ansteigt,  oft an 
altersbedingten Hirnläsionen, die nicht unmittelbar mit Alzheimer in Verbindung stehen. Bei 
der genetisch verursachten Form der familialen AK (autosomal-dominant vererbte Alzheimer 
Krankheit, ADAK) treten die ersten Symptome bereits aber der 3. Dekade auf, also weitaus 
früher als bei der sporadischen Form der AK). Aufgrund des frühen Krankheitsbeginns, sind 
die AD-spezifischen Gehirnveränderunge bei der ADAK nicht durch alterskorrelierte Co-
patholgien wie zB zerebrovaskuläre Erkrankungen konfundiert. Daher kann die ADAK trotz 
geringer Häufigkeit (< 5% aller AK Fälle) als Modell dienen, um AD spezifische Marker für 
die frühe Krankheitserkennung zu etablieren. 
Vorausgegangene Studien zeigten, dass Marker der Abnahme des Hirnvolumens 
(Hirnatrophie), zerebraler Glukose-Hypometabolismus, sowie Ablagerungen seniler Plaques 
aus Beta-Amyloid Peptiden und Neurofibrillenbündel bestehend aus dem Tau-Protein einen 
bei der AK sowie ADAK abnorm verändert sind  (Clifford R. Jack et al., 2010; Dickerson and 
Wolk, 2013). Aktuelle Richtlinien zur Alzheimer Frühdiagnose empfehlen, dass eine 
Kombination aus Bildgebung, Liquorbiomarker und neuropsychologischen Untersuchungen 
zu einer verbesserten Diagnosestellung hergenommen werden (Sperling et al., 2011). In der 
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vorliegenden Arbeit kam ein naiver Bayes Algorithmus für die Identifikation der wichtigsten 
Klassifikationsmerkmale (feature selection) zum Einsatz. Zunächst etablierten wir multi-
modale Vorhersagemodelle basierend auf den Bildgebungsdaten (MRT, FDG-PET), 
Liquormarkern und neuropsychologischen Tests in ADAK Patienten aus der DIAN-Studie. 
Danach wurde das Modell mit der besten Vorhersageleistung ausgewählt, um Probanden mit 
einer sporadischen AK aus der ADNI-Studie zu klassifizieren. Unser Modell konnte mit 
hoher Genauigkeit gesunde Kontrollprobanden von Alzheimerpatienten unterscheiden und 
besonders kritisch progrediente Probanden mit leichter kognitiver Störung – also diejenigen, 
die zum Demenz-Stadium konvertieren - von stabil bleibenden Probanden trennen. 
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1 Introduction 
  
1.1. Sporadic and autosomal-dominant Alzheimer’s disease  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder ranging from an 
asymptomatic preclinical phase to dementia (Mattson, 2004). The clinical syndrome is 
characterized by cognitive impairment including loss of memory, problems with language, 
executive function, and visuospatial abilities and so on (Wilson et al., 2012). Even though the 
cause of the disease is unknown, pathological features of AD include loss of neurons, 
accumulation of amyloid plaques, neurofibrillary tangles (Terry et al., 1991; Touchon and 
Ritchie, 1999).   
Globally, based on the statistic of World Alzheimer Report in 2018, there were approximately 
50 million people with dementia (Christina, 2018). By 2040, the number of people who have 
dementia will be doubled (Prince et al., 2016).  The estimated cost for the treatment and care 
of individuals with dementia in 2018 was a trillion dollars worldwide. In the United States, 
Alzheimer’s disease (AD) was ranked as the second most frequent disease leading to fatal 
health problems based on one Medicare survey (Mayeux et al., 2011; Prince et al., 2015; Niu 
et al., 2017).  
Sporadic Alzheimer’s disease (SAD) is an age-related neurodegenerative disorder, where the 
risk of SAD-related dementia symptoms starts to increase after the age of 65 years. In a small 
subset (less than 5%) of AD patients, AD is caused by genetic mutations and is called autosomal 
dominant (ADAD) (Cruts and Van Broeckhoven, 1998).  The known genetic mutations causing 
ADAD occur in genes encoding the amyloid precursor protein (APP) and the genes for the 
presenilin 1 (PSEN1) and presenilin 2 (PSEN2) proteins, among which mutation in PSEN1 is 
most common in ADAD (Campion et al., 1999). Even though ADAD only accounts for a small 
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proportion of AD, the familial early onset-form of AD provides an excellent opportunity to 
investigate the course of the disease.  A longitudinal multicenter study, i.e. the Dominantly 
Inherited Alzheimer’s Network (DIAN), has been started in 2008 to assess biomarker, 
neuroimaging and cognitive changes in ADAD. Based on the parental onset of symptom, it 
gives an opportunity to track the brain changes of asymptomatic offspring (mutation carriers) 
10-20 years before the estimated onset (Bateman et al., 2012).   
The main pathogenesis in both sporadic and autosomal dominant AD include the accumulation 
of beta-amyloid plaques (Ab) and neurofibrillary tangles consisting of hyperphosphorylated 
tau protein which could be measured in cerebrospinal fluid (CSF) or by positron emission 
tomography (PET) imaging (Klunk et al., 2004; Buerger et al., 2006; Walsh and Selkoe, 2007; 
Fodero-Tavoletti et al., 2011). As the main component of amyloid plaque, Ab1-42 is the most 
important pathological peptide that aggregates and forms diffuse plaques, entailing a cascade 
of brain alterations such as the  activation of astrocytes and microglia, increased development 
of pathologic tau, and ultimately widespread neuronal and synaptic dysfunction (Blennow, de 
Leon and Zetterberg, 2006). Due to the aggregation of Ab deposits in plaque and then less 
diffusion in CSF, Ab1-42 level can be detected in the CSF, where in AD CSF levels are reduced 
presumably due to the deposition of the Ab  peptide in the plaques and thus reduced availability 
of soluble Ab in the CSF (Tapiola et al., 2009).  
APP, PSEN1 and PSEN2 are associated with the pathogenesis of the amyloid-β. These three 
genes are involved in the proteolytic cleavage of the APP protein, leading to the beta-amyloid 
protein, where the APP and PSEN mutations enhance the production of the Ab protein (Ryan 
and Rossor, 2010).  
Besides Aβ, phosphorylated tau is another important AD pathology which is the main 
component of neurofibrillary tangles. Tau is a soluble microtubule-associated protein whose 
main function is to stabilize intracellular microtubules. Phosphorylated tau aggregates into 
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paired helical filaments (PHFs), and further forms neurofibrillary tangles (NFTs), eventually 
causing neuronal death (Lee et al., 2005). The distribution of tau can also refer to the Braak 
staging which was described by Heiko Braak in 1991 (Braak and Braak, 1991; Braak et al., 
2006). The stage 1 and 2 marked as lesion firstly developed in the transentorhinal region then 
progress to the entorhinal region. Stage 3 and 4 marked as the involvement of hippocampus and 
entorhinal cortex. Stage 5 and 6 marked as tau widely progress to other neocortex regions. 
Evidence from Iqbal suggested that he pathological tau protein, like prion protein, can spread 
through neurons in the brain and eventually affect the remote brain area as the disease 
progresses (Iqbal et al., 2005). Presumably due to the degeneration of neurons, intraneuronal 
tau and phosphorylated tau are released into the extracellular space, which becomes detectable 
in the CSF. CSF total tau is a biomarker of neurodegeneration since it is enhanced also in other 
neurodegenerative diseases without NFT, whereas phosphorylated tau is often regarded as a 
marker of neurofibrillary tau pathology (Shaw et al., 2009). 
To detect AD-related early changes in the brain, neuroimaging techniques including MRI and 
PET have been widely used in recent years. The pattern of brain atrophy can be examined by 
structural MRI via gray matter volume change. AD-related brain atrophy occurs in multiple 
areas including the preferentially the medial temporal lobe and posterior parietal cortex at an 
early disease stage and involving other brain areas eventually as well. MRI assessed 
hippocampus volume is a key neuroimaging marker of AD, that was found to be reduced by 
32.5% in AD dementia patients compared to healthy subjects (Frisoni et al., 2008).  In MCI 
patients, there is a significant difference in limbic and fronto-temporo-parietal neocortical 
atrophy compared to the HC group. The general brain atrophy pattern in MCI by structural MRI 
is an important indicator to predict the progression from MCI to AD (Misra, Fan and Davatzikos, 
2009). The best-established functional neuroimaging marker includes [18F]fluorodeoxyglucos 
PET (FDG-PET) assessed glucose metabolism in temporoparietal brain regions (Furst et al., 
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2012). In AD patients, brain metabolism is reduced between 30% to 70% compared with 
cognitively normal elderly people (Silverman et al., 2001).  
 
1.2. Changes in Alzheimer’s disease  
Alzheimer’s disease is slowly progressive and usually can be classified as three stages based 
on the severity of cognitive impairment: cognitively normal, mild cognitive impairment and 
dementia. In the very early stage of AD, there is subtle or no impairment shown in cognitive 
function, but the AD pathophysiology in the brain is already ongoing. Mild cognitive 
impairment (MCI) is an intermediate state between normal cognition and dementia and it is 
always considered as an early stage of AD due to up to two-thirds of patients with MCI 
underlying AD pathology.  Even though there is wide heterogeneity, patients of MCI have a 
higher risk to progress to dementia.  
Many years - even decades - before the symptom onset of AD, pathological changes begin to 
accumulate in the brain. Understanding the order and rate of pathophysiological changes in the 
progress of AD is important for preclinical diagnosis. Ab accumulation starts earlier than other 
pathologies and becomes abnormal up to 20-25 years before the onset of dementia symptoms 
(Jansen et al., 2015). Following Ab, Synaptic dysfunction appears in the preclinical stage of 
AD which can be accessed by [18F]fluorodeoxyglucos PET (FDG-PET) and functional MRI 
(fMRI).  FDG-PET hypometabolism starts to develop in the brain especially in the 
temporoparietal cortex. Following FDG hypometabolism,  CSF tau levels begin to be elevated 
and become abnormal progressively.  Grey matter volume changes, which become abnormal at 
last, can be detected by structural MRI which reflects brain atrophy and massive neuronal loss. 
Changes of each biomarker start from the follow a sigmoid shape which implies a rapid 
progression in the middle period and little change in initial and final periods (Clifford R. Jack 
et al., 2010; Ewers et al., 2011; Sperling et al., 2011).   
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Figure 1. Hypothetical model of dynamic biomarkers of the AD expanded to explicate the preclinical phase. 
Aβ is identified by CSF Aβ42 or PET amyloid imaging (red). Synaptic dysfunction is assessed by FDG-PET 
or fMRI (orange). Tau is identified by CSF (green). Brain structure is evidenced by structural MR(blue) 
(adopted from (Sperling et al., 2011)). 
 
For SAD, the individuals who will develop AD dementia cannot be confirmed until obvious 
disease characteristics being detected (Clifford R. Jack et al., 2010). Because of the predictable 
parental onset age of ADAD patients, their pathophysiological changes can be assessed in 
relation to the estimated years to symptom onset (EYO).  
The Dominant Inherited Alzheimer’s Network (DIAN) is a multicenter study for the 
longitudinal assessment of neuroimaging, biomarker, and neuropsychological changes in 
ADAD (http://www.dian-info.org/de/). Levels of Aβ42 assessed in CSF or by amyloid PET 
becoming abnormal as early as 25 years before their estimated time point of symptom onset. 
Pathologic tau as assessed by CSF tau phosphorylated at threonine 181 (p-tau181) shows a 
significant increase approximately 15 years before the expected age at symptom onset in ADAD. 
Besides pathological changes, structural changes such as hippocampal atrophy were observed 
15 years before symptom onset, followed by cerebral glucose hypometabolism and cognitive 
impairment (measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB)) 
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approximately 10 years before expected symptom onset (Bateman et al., 2012). Temporal 
ordering of abnormalities in biomarkers is similar to the change during the course of SAD which 
suggested common pathophysiology between SAD and ADAD (Jack et al., 2013; Villemagne 
et al., 2013). The progress of biomarker change in SAD is similar compared to ADAD, but the 
symptoms are less severe and the onset is later. Similar to ADAD,  CSF Ab1-42 also decreases 
in SAD but the degree of decline is only half of that in ADAD (Ringman et al., 2012). The ratio 
of Ab1-40/ Ab1-42 is observed decrease in the progress of ADAD, however, in SAD,  the reported 
results can be variable (Mayeux et al., 2003; van Oijen et al., 2006; Blennow et al., 2010).  For 
the tau pathology, higher severity has also been showen in ADAD compared to SAD 
(Sunderland et al., 2003). 
 
Figure 2. Temporal ordering of dynamic biomarkers in ADAD. Temporal ordering is assessed based on 
estimated years from expected symptom onset and shown with standardized difference between mutation 
and non-mutation carriers. The abnormalities of biomarkers appear in the following order: CSF Aβ42, 
fibrillar Aβ deposition, CSF tau, hippocampal atrophy, glucose hypometabolism, followed by cognitive 
change. (adopted from (Bateman et al., 2012) ). 
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1.3. Machine learning for brain imaging and bioinformatics 
In recent years, the development of machine learning was growing very fast in many fields. 
Neuroscience is one of the fields with the fastest growth in machine learning applications 
(Vogt, 2018; Vu et al., 2018). In the past decade, the number of publications about machine 
learning in neuroscience and AD increased rapidly (Figure 3).  
 
 
Figure 3. Trends of machine learning publications in neuroscience and Alzheimer’s disease in the past 
decade. Numbers of publications from Web of Science based on search of keywords: machine learning 
Alzheimer’s disease, machine learning neuroscience. 
 
For volumetric MRI derived features, there are mainly two types of features: voxel-based 
features and region of interest (ROI) based features. Recent machine learning 
studies investigating the use of structural MRI to predict the conversion in the early stage of 
AD (MCI converters vs. non-converters) are listed in Table 1. Voxel-based features yielded 
AUC/accuracy of 70-86%. ROI-based features showed AUC/accuracy of 71-93%. 
Hippocampus features had the AUC/accuracy of 74-79% in distinguishing convertors with 
non-converters. 
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Table 1: Structural MRI as predictor: results from recent (past 5 years) studies on the classification of MCI who 
developed AD dementia (MCI converter) vs those who remained stable during the follow up period (MCI non-
converter) 
Study Dataset 
Sample size: 
MCI cov: 
MCI ncov 
AUC SEN SPE 
Follow-up 
duration 
(month) 
Voxel-based features 
(Moradi et al., 2015) ADNI 164:100 76.61 88.85 51.59 0-36 
(Wang et al., 2016) ADNI 64:65 69.7* 64.06 75.38 0-36 
(Beheshti, Demirel and 
Matsuda, 2017) ADNI 71:65 76.92 73.23 75.08 0-36 
(Lin et al., 2018) ADNI 169:139 86.1 84 74.8 0-36 
ROI-based features 
(Guerrero et al., 2014) ADNI 116:114 71* 75.0 67.0 0-24 
(Chen, Wei and Liu, 
2015) ADNI 167:236 71.8 58.1 76.3 0-24 
(Cheng et al., 2015) ADNI 43:56 76.40 74.3 72.1 0-24 
(Clark et al., 2016) ADNI 24:83 76.0 68.2 75.6 0-48 
(Hor and Moradi, 2016) ADNI 96:126 84.8 81.9 75.0 0-36 
(Korolev, Symonds and 
Bozoki, 2016) ADNI 120:139 76.0 68.5 69.6 0-36 
(Liu et al., 2016) ADNI 117:117 80.90 85.95 78.41 0-18 
(Long et al., 2017) ADNI 95:132 93.2 86.32 90.91 0-36 
Hippocampus 
(Komlagan et al., 2014) ADNI 166:236 75.6* 61.5 85.6 - 
(Hu et al., 2015) ADNI 71:62 79.00 71.83 83.26 0-36 
(Sørensen et al., 2016) ADNI 93:140 74.2 - - 0-24 
Abbreviations: ADNI = Alzheimer's Disease Neuroimaging Initiative; AUC = Area Under Curve; SEN = 
Sensivity; SPE = Specificity 
* accuracy 
Voxel-based methods quantify the brain structure changes by density map which were used in 
several studies in recent years (Moradi et al., 2015; Wang et al., 2016; Beheshti, Demirel and 
Matsuda, 2017; Lin et al., 2018). ROI-based methods are based on pre-defined anatomical 
atlases such as Desikan-Killiany atlas (Desikan et al., 2006) and automated anatomical 
labeling (AAL) atlas (Tzourio-Mazoyer et al., 2002). The quantitative measures used in ROI-
based methods include cortical thickness (Clark et al., 2016; Korolev, Symonds and Bozoki, 
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2016), regional volume (Chen, Wei and Liu, 2015; Cheng et al., 2015; Clark et al., 2016; Hor 
and Moradi, 2016; Korolev, Symonds and Bozoki, 2016), and average intensity value 
(Guerrero et al., 2014; Liu et al., 2016; Long et al., 2017). In both voxel or ROI based 
methods, some studies focused on the hippocampus (Komlagan et al., 2014; Hu et al., 2015; 
Sørensen et al., 2016) and entorhinal cortex (Dickerson et al., 2001). The voxel-based method 
achieved prediction accuracy or AUC of 76-85%. The ROI-based features were 57-82% 
accurate in differentiating MCI converters and non-converters. 
Table 2: FDG-PET as predictor: results from recent (past 5 years) studies on the classification of MCI who 
developed AD dementia (MCI converter) vs those who remained stable during the follow up period (MCI 
nonconverter) 
Study Dataset 
Sample size: 
MCI cov: 
MCI ncov 
AUC SEN SPE 
Follow-up 
duration 
(month) 
Voxel-based features 
(Cabral et al., 2015) ADNI 44:56 85* - - 0-24 
(Dukart, Sambataro and 
Bertolino, 2015) ADNI 29:135 82.4 90.0 83.9 2-10 years 
(Wang et al., 2016) ADNI 64:65 75.97* 68.74 83.08 0-36 
ROI-based features 
(Cheng et al., 2015) ADNI 43:56 74.1 76.4 67.9 0-24 
(Jie et al., 2015) ADNI 242:174 57.00 48.37 59.11 0-36 
(Xu et al., 2015) ADNI 27:83 74.1 67.4 66.7 0-36 
(Suk, Lee and Shen, 
2015) ADNI 43:56 68.9* - - 0-18 
(Choi and Jin, 2018) ADNI 79:92 82 70.9 79.3 0-36 
Abbreviations: ADNI = Alzheimer's Disease Neuroimaging Initiative; AUC = Area Under Curve; SEN = 
Sensivity; SPE = Specificity  
* accuracy 
For FDG-PET, - as for structural MRI - there are two types of features for classification with 
FDG-PET: voxel-based features and ROI or atlas-based features. Therefore, features of FDG-
PET studies for AD prediction can be roughly divided into voxel-based FDG-PET (Cabral et 
al., 2015; Dukart, Sambataro and Bertolino, 2015) (Wang et al., 2016), and ROI-based 
(Cheng et al., 2015; Jie et al., 2015; Suk, Lee and Shen, 2015; Choi and Jin, 2018) (Xu et al., 
2015) FDG-PET studies (Table 2).  
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Neuropsychological assessments have identified the cognitive and behavior changes in early 
AD. For cognitive alterations as a predictor for the identification of subjects who will convert 
to AD dementia, there were several studies using test such as verbal cued recall and verbal 
fluency tests, ADAS-Cog test, Functional Activities Questionnaire (FAQ), Rey Auditory 
Verbal Learning Test (RAVLT), Mini Mental State Examination (MMSE) and Geriatric 
Depression Scale (GDS) (Segovia et al., 2014; Dukart, Sambataro and Bertolino, 2015; Clark 
et al., 2016; Korolev, Symonds and Bozoki, 2016; Wang et al., 2016) (Table 3). With 
neuropsychological measures, the studies showed AUC/accuracy of 72-87%. 
Table 3 Neuropsychological scores as predictors: results from recent (past 5 years) studies on the classification 
of MCI who developed AD dementia (MCI converter) vs those who remained stable during the follow up period 
(MCI non-converter) 
Study Dataset PSY tests 
Sample size: 
MCI cov: 
MCI ncov 
AUC SEN SPE 
Follow-up 
duration 
(month) 
(Segovia et al., 2014) EADC Verbal cued recall, 
Verbal fluency  
26:20 73.91* 73.08 75.00 0-36 
(Dukart, Sambataro 
and Bertolino, 2015) ADNI 
MMSE, GDS, ADAS, 
RAVLT, FAQ 29:135 71.6 85.7 51.3 0-24 
(Clark et al., 2016) ADNI Verbal fluency  24:83 87.2 70.8 88 0-48 
(Korolev, Symonds 
and Bozoki, 2016) 
ADNI ADAS-Cog, FAQ, 
RAVLT 
120:139 83.0 76.9 75.3 0-36 
(Wang et al., 2016) ADNI ADAS-Cog 64:65 79.07* 73.44 84.62 0-36 
Abbreviations: EADC =European Alzheimer's disease consortium; ADNI = Alzheimer's Disease Neuroimaging 
Initiative; AUC = Area Under Curve; SEN = Sensivity; SPE = Specificity; MMSE = Mini Mental State 
Examination; GDS = Geriatric Depression Scale; ADAS = Alzheimer’s Disease Assessment Score; RAVLT 
= Rey Auditory Verbal Learning Test 
* accuracy 
 
Previous studies established CSF biomarkers Aβ42, t-tau, and p-tau to predict MCI 
conversion to AD as single modality (Table 4). For the classification of MCI converters 
versus non-converter, the results CSF biomarkers were between 58% to 68% (AUC/accuracy) 
when used as a single marker. 
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Table 4: CSF biomarkers as predictor: results from recent (past 5 years) studies on the classification of MCI 
who developed AD dementia (MCI converter) vs those who remained stable during the follow up period (MCI 
nonconverter) 
 
Study Dataset 
Sample size: 
MCI cov: 
MCI ncov 
AUC SEN SPE 
Follow-up 
duration 
(month) 
Ab1-42, p-tau, total Tau 
(Cheng et al., 2015) ADNI 43:56 67.6 74.6 61.5 0-24 
(Jie et al., 2015) ADNI 242:174 63.00 53.02 63.04 0-36 
(Suk, Lee and Shen, 
2015) ADNI 43:56 57.7* - - 0-18 
Abbreviations: ADNI = Alzheimer's Disease Neuroimaging Initiative; AUC = Area Under Curve; SEN = 
Sensivity; SPE = Specificity 
* accuracy 
 
To predict the conversion in the early stage of AD, combining multiple modalities may 
provide complementary information and then improve the classification performance 
compared to a single modality. Some recent studies combined two modalities such as MRI & 
FDG-PET (Liu et al., 2014; Suk, Lee and Shen, 2014; Hor and Moradi, 2016), MRI & 
neuropsychological tests (Korolev, Symonds and Bozoki, 2016; Minhas et al., 2017), MRI & 
CSF biomarkers (Frölich et al., 2017). Some other multi-model studies did the classification 
combined with three modalities such as MRI & FDG-PET & neuropsychological tests 
(Segovia et al., 2014; Dukart, Sambataro and Bertolino, 2015; Wang et al., 2016), MRI & 
FDG-PET & CSF biomarkers (Suk, Lee and Shen, 2014; Zhu, Suk and Shen, 2014; Cheng et 
al., 2015; Jie et al., 2015), MRI & FDG-PET & 18F-florbetapir-PET (Xu et al., 2015), MRI & 
neuropsychological tests & demographic data (Moradi et al., 2015; Clark et al., 2016; Tong et 
al., 2017). The two-modality-combination achieved prediction accuracy or AUC of 71-87% 
(Table 5). With three-modality-combination, the studies showed the AUC/accuracy of 74-
90% (Table 5). 
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Table 5: Multi-modal predictors: results from recent (past 5 years) studies on the classification of MCI who 
developed AD dementia (MCI converter) vs those who remained stable during the follow up period (MCI non-
converter) 
Study Dataset Modalities 
Sample size: 
MCI cov: 
MCI ncov 
AUC SEN SPE 
Follow-up 
duration 
(month) 
2-modality-combination 
(Liu et al., 2014) ADNI MRI+FDG 43:56 69.57 64.88 70.00 0-18 
(Suk, Lee and Shen, 
2014) ADNI MRI+FDG 76:128 74.66
 48.04 95.23 - 
(Hor and Moradi, 
2016) ADNI MRI+FDG 27:144 87.2 83.10 80.3 0-36 
(Korolev, Symonds 
and Bozoki, 2016) ADNI MRI+PSY 120:139 87.0
 83.4 76.4 0-36 
(Minhas et al., 2017) ADNI MRI+PSY 67:78 - 92.3 87.5 0-36 
(Frölich et al., 2017) DCN MRI+CSF 28:87 82 85 64 0-36 
3-modality-combination 
(Segovia et al., 2014) EADC MRI+FDG+PSY 26:20 86.96* 92.32 80.00 0-36 
(Dukart, Sambataro 
and Bertolino, 2015) ADNI MRI+FDG+PSY 29:135 83.3
 100 75.5 0-24 
(Wang et al., 2016) ADNI MRI+FDG+PSY 64:65 84.5* 82.81 86.15 0-36 
(Jie et al., 2015) ADNI MRI+FDG+CSF 242:174 72.00 66.05 76.61 0-36 
(Zhu, Suk and Shen, 
2014) ADNI MRI+FDG+CSF 43:56 78.8
 48.5 94.4 0-36 
(Suk, Lee and Shen, 
2015) ADNI MRI+FDG+CSF 43:56 83.3*
 - - 0-18 
(Cheng et al., 2015) ADNI MRI+FDG+CSF 43:56 84.80 84.50 72.70 0-24 
(Moradi et al., 2015) ADNI MRI+PSY+AGE 164:100 90.20 86.65 73.64 0-36 
(Tong et al., 2017) ADNI MRI+PSY+AGE 171:129 87.0 86.7 72.6 0-36 
(Clark et al., 2016) ADNI MRI+PSY+DEM 24:83 81.4 62.5 89.2 0-48 
(Xu et al., 2015) ADNI MRI+FDG+FBP 27:83 80.7 74.1 81.5 0-36 
Abbreviations: EADC =European Alzheimer's disease consortium; ADNI = Alzheimer's Disease Neuroimaging 
Initiative; DCN = Dementia Competence Network; AUC = Area Under Curve; SEN = Sensivity; SPE = 
Specificity; FBP= florbetapir; DEM = Demographic Variable 
* accuracy 
 
 
 
13 
From the articles which focused on automated detection of MCI conversion to AD in the past 
five years, the majority of studies combined multiple modalities rather than single modality 
(Some of the single modality results listed in Table 1-4 are parts of the multimodality studies 
listed in Table 5). Based on the use of imaging data – MRI, FDG-PET or the combination of 
those, the classification accuracy is generally below 80%. Only two of five articles listed in 
Table 3 which used neuropsychological tests showed a classification accuracy higher than 
80%. Using only CSF biomarkers, the classification accuracy was in none of the studies 
above 70%. Compared to the single modality, multi-modality predictors achieved better 
performance which was generally above 80% classification accuracy.  
Machine learning can be roughly categorized into supervised learning, unsupervised learning 
and semi-supervised learning. In supervised learning, the prediction model is established 
based on the data which is associated with the output and then applied to the new data for 
prediction (such as classification). In unsupervised learning refers to the models are trained 
based on the unlabelled data. In semi-supervised learning, the models are established based on 
both labeled and unlabeled data. Its purpose is to use limited labeled data and a large amount 
of unlabeled data to enhance the learning ability.  
To improve classification performance, feature selection is a critical step by selecting the 
most discriminative features. Among the supervised methods, Information Gain (IG) (Hor and 
Moradi, 2016), t-test (Xu et al., 2015; Beheshti, Demirel and Matsuda, 2017; Minhas et al., 
2017), Mutual Information (MI) (Cabral et al., 2015), and Markov Blanket approach (Dukart, 
Sambataro and Bertolino, 2015) were used in recent five years’ studies of predicting AD 
conversion. When the number of features is very high and exceeds the number of training 
samples such as voxel-based features of imaging data, it will lead to poor performance of 
classification. To reduce the feature dimensionality, unsupervised learning methods were 
usually applied including Principle Component Analysis (PCA) (Wang et al., 2016; Choi and 
Jin, 2018; Lin et al., 2018), Independent Component Analysis (ICA) (Segovia et al., 
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2014), Least Absolution Shrinkage and Selection Operator (LASSO) (Guerrero et al., 2014; 
Zhu, Suk and Shen, 2014; Tong et al., 2017; Lin et al., 2018). For classification, a number of 
algorithms on predicting MCI conversion to AD have been used based on supervised and 
semi-supervised learning. The most used supervised learning method in recent research is 
Support Vector Machine (SVM) (Liu et al., 2014, 2016; Segovia et al., 2014; Cabral et al., 
2015; Cheng et al., 2015; Hu et al., 2015; Jie et al., 2015; Sørensen et al., 2016; Beheshti, 
Demirel and Matsuda, 2017). Besides, Naïve Bayes (NB) (Cabral et al., 2015; Dukart, 
Sambataro and Bertolino, 2015), Random Forest (RF) (Hor and Moradi, 2016; Tong et al., 
2017), and logistic regression (Clark et al., 2016) were also widely used supervised learning 
methods in predicting AD. With semi-supervised methods, few recent studies investigated the 
used of Low Density Separation (LDS) (Moradi et al., 2015) and multimodal relevance vector 
regression (Zhu, Suk and Shen, 2014) for the predicting of MCI conversion. 
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1.4. Aim of the study 
The overall goal of the current thesis was to establish a cross-validated multimodal biomarker 
model for the early detection of AD. The specific aims were  
1) Train the best classification model based on single modalities and combinations of up to 4 
modalities for discriminating ADAD against controls.  
2) Cross-validate the best classification models in a large sample of SAD subjects at different 
disease stages   
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2 Materials and methods 
  
2.1. Databases  
DIAN: 
Dominantly Inherited Alzheimer’s Network is a multisite study established in 2008 (Moulder 
et al., 2013). The DIAN study recruits individuals who carry the gene mutations (PSEN1, 
PSEN2 or APP) and their siblings who do not carry any of the mutations. The individuals 
who are non-mutation carriers contribute as control sample. The ratio of mutation and non-
mutation carriers is approximately equal. Inclusion criteria are: 1) provide informed consent 
before other procedures; 2) older than 18 years; 3) nursing home-level care is not needed; 4) 
have at least one non-full-blooded sibling as collateral source; 5) language fluency needs to be 
equal or higher than 6th grade level. The participants who have psychiatric illness were not 
eligible. The main goals of DIAN study are to investigate asymptomatic brain changes with 
cognitive, imaging and fluid biomarkers to track the disease. 
ADNI: 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a multicenter study that was 
established by various institutes and organizations (e.g. National Institute on Aging (NIA)). 
ADNI started in October 2004 led by Dr. Michael W. Weiner from department of Radiology 
and Biomedical Imaging in University of California, San Francisco (UCSF). The first stage 
was ADNI-1 which has recruited around 800 subjects (HC/MCI/AD = 200/400/200) for five 
years. Different types of data were collected in ADNI-1 including brain scans (structural 
MRI, FDG-PET, PIB-PET), CSF biomarkers (Ab1-42, p-tau, total Tau) and genetic profiles. 
The initial aim was developing biomarkers for tracking the early stage of AD. The second 
stage ADNI-GO started in September 2009 and recruited another 200 new early MCI 
subjects. At the same time, the subjects from ADNI-1 were keeping examined.  Besides the 
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data types measured ADNI-1, diffusion MRI (diffusion tensor imaging, DTI) and resting 
state fMRI were added in ADNI-GO. The focus of this stage is biomarkers of earlier stage of 
AD. Followed ADNI-GO, the third stage ADNI-2 begun in September 2011 and lasted for 
five years. In addition to follow up the participants of ADNI-1/GO, 150 HC, 300 MCI and 
150 AD subjects were added. Main differences from previous stages were additional amyloid 
PET (florbetapir PET) added. The past three stages ADNI-1/GO/2 recruited more than 1500 
subjects from 55 to 90 years old and widely used in clinical and scientific research.  
 
2.2. Participants  
DIAN: 
A total of 174 subjects were included from DIAN cohort who were enrolled from September 
2009 through April 2014 collected at 13 sites (7 sites in the United States, 3 sites in Australia, 
1 site in the United Kingdom, 2 sites in Germany). Of these subjects, 101 were carriers of 
mutation causing AD in the genes presenilin1 (PSEN1, n = 77), presenilin2 (PSEN2, n = 9), 
or amyloid precursor protein (APP, n = 15). And 73 subjects were non-mutation carriers from 
the same families that were used as control samples (Table 6). In addition to satisfy the 
inclusion criteria of DIAN mentioned above, all DIAN subjects included in this study had to 
be assessed with T1-weighted MRI, FDG-PET, neuropsychological tests and CSF biomarkers 
of Ab1-42 and tau which is shown in Figure 4A. For each subject, the predictable year to 
symptom onset was estimated based on the symptomatic onset of parents. EYO thereby was 
defined as current age minus the year of symptom onset. 
ADNI: 
We included 545 subjects with baseline diagnoses from ADNI GO/2 database as our 
validation sample set. Among all the subjects, there are 205 HC subjects, 262 MCI subjects, 
and 78 AD patients (Table 6). HC refers to the subjects of cognitive normal with mini-mental 
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state examination (MMSE) score between 24 and 30, clinical dementia rating (CDR) of 0 and 
no signs of cognitive impairment and significant depression. MCI indicates the subjects who 
have mild cognitive impairment with MMSE score between 24 and 30, CDR score of 0.5 and 
subjective memory concern. AD subjects had MMSE score between 20 and 26, a CDR score 
equal or greater than 0.5 and memory complaints. In addition to meet these requirements, 
ADNI inclusion criteria mainly included: Geriatric Depression Scale < 6, age from 55 to 90, 
fluently speaking English or Spanish, willing to attend longitudinal measures (more details in 
ADNI protocol). The ADNI subjects involved in our study also need to have 3T T1-structural 
MRI, FDG-PET, neuropsychological tests and CSF biomarkers at baseline and at least one 
clinical follow-up assessment after 3 years (Figure 4B). HC converters were defined based on 
conversion MCI or AD dementia within 36 months. MCI converters were defined based on 
conversion to AD dementia within 36 months. The other HC or MCI subjects who didn’t 
convert and had at least 36 months follow-up data were included as non-converters. Median 
clinical follow-up time was 48 months for HC subjects (from 12 up to 60 months) and also 48 
months for MCI subjects (from 36 up to 60 months). 
 
Table 6A: Baseline demographics of DIAN 
Demographic Mutation Carriers Non-carriers 
n 101 73 
Agea 39.9(10.4) 39.2(10.5) 
Male(%) 48(48) 33(45) 
Educationa 13.7(3.0)** 14.9(2.3) 
APOE4+(%) 59(58.4)*** 2(2.7) 
ADAS11a 26(26.0) 23(32.4) 
MMSEa 26.6(9.1)* 29.0 (1.3) 
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Table 7B: Baseline demographics of ADNI 
Demographic HC AD HC cov HC ncov MCI cov MCI ncov 
n 205 78 14 62 78 184 
Agea 72.7(6.1)** 75.6(7.7) 76.3(5.9) 74.1(6.0) 72.9(7.0) 71.1(7.2) 
Male(%) 110(46) 60(61) 11(61) 37(50) 42(52) 116(56) 
Educationa 16.6(2.5)** 15.6(2.6) 15.6(2.7) 16.6(2.6) 16.1(2.6) 16.3(2.6) 
APOE4+(%) 35(29)*** 67(69) 4(22) 21(28) 60(74)** 80(38) 
ADAS11a 5.6(2.9)*** 19.7(6.4) 8.7(2.8)* 6.0(2.9) 13.5(4.8)** 8.1(3.3) 
MMSEa 29.0(1.2)*** 22.9(2.0) 28.6(1.4) 29.1(1.4) 27.2(1.7)** 29.1(1.4) 
 
Cov = converter, ncov = non-converter 
* p < 0.05. 
** p < 0.01. 
*** p < 0.001 
a values are mean and standard deviation 
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Figure 4. Flowchart for subject inclusion. In (A) DIAN and (B) ADNI, we included the subjects who had 
the data of all four modalities (MRI, FDG-PET, psychological data and CSF biomarkers). Abbreviation: 
Cov = converter, nCov = non-converter 
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2.3. MRI acquisition and assessment  
DIAN: 
For each DIAN subject, structural MRI was acquired with Siemens 3T scanner and pass the 
initial and follow-up quality control procedures. Across different sites, scans were performed 
based on unified protocol (according to ADNI protocol). Three-dimensional T1-weighted 
sagittal MP-RAGE scans lasted for five minutes with the following parameters: 
TR/TE=2300ms/2.95ms, flip angle = 9°, 1.1 × 1.1 × 1.2 mm resolution. All the scans were 
screened by DIAN Imaging Core for compliance of the imaging acquisition protocol.  
Processing of 3T MRI scans was done with FreeSurfer 5.1 (FreeSurfer Software Suite is 
available at http:// surfer.nmr.mgh.harvard.edu/) based on Dell PowerEdge 1950 servers with 
Intel Xeon processors contained cortical surface reconstruction and volumetric segmentation 
(Fischl, 2012). DIAN MRI processing included motion correction, segmentation of 
volumetric structure (gray matter and white matter) (Fischl et al., 2002), intensity 
normalization, cortical surface extraction and parcellation of cortical and subcortical areas 
using Desikan Killiany probabilistic atlas (Desikan et al., 2006). Each region of interest (ROI) 
was corrected for intracranial volume with published method (Jack et al., 1989). All MRI 
processing was done by the DIAN imaging core including ROI extraction. For further 
analysis, we used cortical volume from 41 ROIs for each hemisphere (34 cortical and 7 
subcortical ROIs) (Figure 5). All Desikan Killiany ROIs are listed in Table 8. 
ADNI: 
T1 MRI images of ADNI database were acquired using 3T Siemens scanners. All scans were 
based on ADNI acquisition protocol and posted methods (available at http://www.adni-
info.org). Imaging was performed with three-dimensional MP-RAGE sequence with the 
following parameters: TR/TE/TI=2300/2.98/900ms, field of view (FOV) = 256 × 240 mm2, 
flip angle = 9°, 176 slices, 1.1 × 1.1 × 1.2 mm resolution. Each MP-RAGE image underwent 
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gradient non-linearity distortion correction, B1 non-uniformity correction and non-uniform 
intensity normalization (N3) by ADNI MRI core (http://adni.loni.usc.edu/methods/mri-
tool/mri-pre-processing/). 
The volumetric T1-weighted images were processed using Freesurfer (Version 5.1). The 
procedure done by ADNI Imaging Core included motion correction, geometry distortion 
correction, non-brain tissue removal, Talairach space transformation, white matter and gray 
matter segmentation and intensity normalization. Desikan-Killiany atlas-based ROI extraction 
was also provided by ADNI Core. We used same extracted ROIs (41 ROIs for each 
hemisphere) subdivided from cortical and subcortical regions of ADNI MR scans as DIAN 
data for further analysis. 
 
2.4. FDG-PET acquisition and assessment  
DIAN: 
18F-FDG scans were performed using a bolus injection of 5 mCi of FDG. The acquisition 
started 40 minutes after the injection and lasted for 20 minutes (4x5 minute frames). Each 
FDG-PET image was taken quality check according to the ADNI PET QC. With the standard 
protocol, PET images were motion-corrected and registered to individual FreeSurfer derived 
MRI regions of interest. FDG-PET was then converted to standardized uptake value ratio 
(SUVR) for each ROI in Desikan-Killany Atlas space with the brainstem reference. Due to 
lower spatial resolution of PET imaging than structural MR imaging, it will lead to loss of 
activity or blurring of adjacent tissues which is called partial volume effects (PVE). So partial 
volume correction (PVC) was done using a method based on regional spread function (RSF) 
by DIAN imaging core (Roussel, Ma and Evans, 1998).  
ADNI: 
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Before PET scanning, each subject need to be checked to ensure blood glucose <180 mg/dL. 
FDG-PET scanning will last for 30 minutes with 4x5 minute frames after 30 minutes of 
injection of 185 MBq (5 mCi) fluorodeoxyglucose.  After scanning, each PET image was 
checked by ADNI PET QC team. In order to get uniform PET scans, same Freesurfer 
preprocessing pipeline (as described previously in DIAN) was applied to ADNI dataset. Since 
FDG-PET SUVR value is not available from ADNI core, we performed the same procedure 
to calculate the corresponding SUVR score by superimposing Desikan-Killiany ROIs to 
FDG-PET. SUVR value of ADNI PET images was normalized to brainstem. 
 
 
 
Figure 5. Regions of Desikan-Killiany atlas. For each hemisphere, it includes 34 cortical regions and 7 
subcortical regions. 
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Table 8: Regions of Desikan-Killiany atlas 
 
Frontal lobe Temporal lobe 
Caudal middle frontal gyrus Banks superior temporal sulcus 
Frontal pole  Inferior temporal gyrus 
Lateral orbital frontal cortex Middle temporal gyrus 
Medial orbital frontal cortex Superior temporal gyrus 
Paracentral lobule Transverse temporal cortex 
Pars opercularis  Entorhinal cortex 
Pars orbitalis Fusiform gyrus 
Pars triangularis Parahippocampal gyrus 
Precentral gyrus Temporal pole 
Rostral middle frontal gyrus Cingulate cortex 
Superior frontal gyrus Caudal anterior-cingulate cortex 
Parietal lobe Insula 
Inferior parietal cortex Isthmus–cingulate cortex 
Postcentral gyrus Posterior-cingulate cortex 
Precuneus cortex Rostral anterior cingulate cortex 
Superior parietal cortex Subcorical structures 
Supramarginal gyrus accumbens  
Occipital lobe amygdala  
Cuneus cortex caudate   
Lateral occipital cortex hippocampus  
Lingual gyrus pallidum  
Pericalcarine cortex putamen 
 
thalamus  
 
 
2.5. Neuropsychological tests  
Participants from DIAN and ADNI underwent a set of neuropsychological assessments. 
Among these assessments, we included seven tests for both DIAN and ADNI studies which 
are listed below. 
1) Mini-Mental State Examination (MMSE) is a widely used test to evaluate cognitive 
impairment and screen for possible dementia. MMSE score ranges from 0 to 30: greater 
than 23 points suggests cognitively normal; 19-23 indicates mild cognitive impairment; 
10-18 means moderate cognitive impairment; below 10 suggests severe cognitive 
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dysfunction. The test evaluates orientation (time and place), registration (repetition 
immediately), attention and calculation, recall, language, repetition and visual 
construction (Folstein, Folstein and McHugh, 1975; Weintraub et al., 2009).  
2) Boston Naming Test is a measure of naming ability and semantic memory. During test, 
participants will be showed 30 pictures and asked to tell the name of the object. In both 
DIAN and ADNI studies, reduced version was used based on original 60 items test 
(Goodglass and Kaplan, 1983). 
3) Category Fluency Test, also called verbal fluency test, is a measure of semantic memory 
and executive function. Participants will be asked to produce words of a given category 
within 60 seconds. We used category fluency test of animal category in this study from 
DIAN and ADNI (Morris et al., 1989). 
4) Trail Making Test, including two different tests (A&B), is a measure of processing speed 
visual–motor skills, and executive functions. For the test A, participants need to connect 
the 25 circles from number 1 through 25 in sequence. For the test B, there are also 25 
circles including 13 numbers (1-13) and letters (A-L) which need to be connected in 
alternative order. Protocols are same for DIAN and ADNI (Reitan and Wolfson, 1985).  
5) Word List Immediate and Delayed Recall test is a measure of episodic memory. 
Participants will be asked to recall a list of words immediately and after a while. In DIAN, 
the word list contains 16 high-frequency words. In ADNI, the word list contains 10 words 
(Rosen, Mohs and Davis, 1984). 
 
2.6. CSF biomarkers  
CSF concentration of amyloid-b42, total tau and phosphorylated tau at threonine 181 (p-tau) 
were included in our analysis. The protocol of gathering CSF in DIAN is consistent with the 
biofluid protocol in ADNI.  
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DIAN: 
CSF (15 ml) was collected in the morning under fasting circumstance by standard lumbar 
puncture into polypropylene tubes. CSF samples were then shipped to and analyzed by DIAN 
biomarker core team at Washington University. CSF amyloid-b42, tau and p-Tau were 
measured by multiplex xMAP Luminex platform (Fagan et al., 2014a). 
ADNI: 
CSF collection pipeline is the same with DIAN. CSF samples were shipped to and analyzed 
by the Roche Elecsys® electrochemiluminescence immunoassays and conducted by the 
ADNI biomarker core team at University of Pennsylvania (Shaw et al., 2009). 
 
2.7. Data preprocessing 
We used DIAN data as our training data to establish the Naïve Bayes algorithm-based 
machine learning model and ADNI data as our independent validation data to test the 
classification model. To meet the prerequisites of classification, we did data preprocessing 
including normalization and standardization. 
2.7.1 Feature normalization 
 
Recent research shows Box-Cox transformation did improve the performance of classifiers 
which are under the assumption of normality (Bicego and Baldo, 2016). We used Naïve 
Bayes algorithm as our classification method. One of the prerequisites of Naïve Bayes with 
Gaussian kernel is that each attribute (feature) need to be normally distributed. Therefore, we 
did normalization as the first step of data preprocessing.  
One of the most useful normalization methods is Box-Cox power transformation which was 
proposed by George Box and David Cox in 1964. The aim of Box-Cox transformation is to 
transform the non-normal data to approximately normal distributed. The reasons for non-
normality usually are: 1) there are extreme values which may lead to a skewed distribution; 2) 
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limit of the data may also result in a skewed distribution; 3) overlap of more than one process 
will cause non-normal distribution. 4) insufficient data discrimination will make data become 
non-normal. To normalize the data, we used the following equation: 
x(𝜆) = 	'𝑥) − 1𝜆 , 𝑖𝑓	𝜆 ≠ 0	ln 𝑥 ,													𝑖𝑓	𝜆 = 0,  
where x is the recorded data (features of different modalities) and x needs to be positive (>0). 
In our projects, some features didn’t meet this condition: e.g. the minimum score of delayed 
word recall test is zero (in both DIAN and ADNI). If y is smaller or equal to zero, we used an 
extended form: 
x(𝜆) = 	'(𝑥 + 𝑐)) − 1𝜆 , 𝑖𝑓	𝜆 ≠ 0	ln(𝑥 + 𝑐) ,													𝑖𝑓	𝜆 = 0,  
where c is a constant which makes any y meet the condition: 𝑥 + 𝑐 > 0. In both equations, 𝜆 
is the transformation parameter estimated using maximum likelihood theory.  The operation 
with different values of parameter 𝜆 is shown in Figure 6. In special cases, when 𝜆 = 0, it’s 
natural log transformation. When 𝜆 = 1, it’s linear transformation and the data stays 
unchanged. When 𝜆 = −1, it’s reciprocal transformation. When 𝜆 = 0, it’s natural log 
transformation. In our project, Box Cox transformation was done with SciPy library of Python 
(available at https://scipy.org/). 
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Figure 6. Box Cox transformation with different 𝜆 parameters 
 
2.7.2 Feature standardization 
 
A prerequisite for the cross-validation between studies is that the features across DIAN and 
ADNI are comparable. In other words, the same feature in DIAN and ADNI need to be in a 
comparable value range.  Even though the assessment of DIAN and ADNI data used very 
similar protocols , some differences still remain (available at http://www.adni-info.org and 
dian.wustl.edu). Different CSF assays were used (xMap in DIAN and Elesys in ADNI) which 
may lead to difference in absolute CSF measurement values. Moreover, the age range of the 
subjects differs between the two studies (20-61 years old of mutation carriers in DIAN, 55-
91years old of MCI in ADNI). Lack of consistency in training and validation set will lead to 
poor performance of classifier. Hence, we did standardization (scaling) as the second step of 
preprocessing. 
𝑥 
x(𝜆) 
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We used the Centiloid method which was originally developed for the standardization of 
amyloid PET imaging and enabled the comparison of results from different tracers and 
methods (Klunk et al., 2015). In this project, the Centiloid method was applied to create 
comparable value ranges (i.e. a scale ranging from 0 to100) across the training set (DIAN) 
and test set (ADNI) for each feature of MRI and FDG-PET images, psychological tests and 
CSF biomarkers. Similar to the procedure for the Centiloid scaling method applied to amyloid 
PET, we firstly defined two reference groups at both ends of the disease spectrum (HC vs AD 
dementia) for both DIAN and ADNI. The HC reference group included cognitive normal 
elder subjects who showed normal CSF Aß values. The AD reference group was included 
cases with AD dementia who showed abnormal CSF Aß values. Specifically, in DIAN, the 
control reference group was defined as non-mutation carriers who meet the conditions: 
EYO>0 & CDR=0 & Aß- (CSF Aß1-42 > 192 pg/ml). AD reference group was defined as 
mutation carriers who meet the conditions: EYO>0 & CDR>=1 & Aß+ (CSF Aß1-42 < 192 
pg/ml) (Shaw et al., 2009). In ADNI, the control reference group was defined as HC subjects 
who meet the conditions: Age<70 & Aß-. AD reference group was defined as AD subjects 
who met the conditions: Aß+. Limitation of age is to minimize age-related effects (non-
Alzheimer related pathologies). Each feature was scaled linearly with the following equation 
(Jack et al., 2015): 
𝑋789:;< = 100 × 𝑋>?@ − 𝑋ABC𝑋A9D − 𝑋ABC 
Where:  𝑋>?@ is individual’s feature value.   𝑋ABC is the 5th percentile of 𝑋EFCGHF: if  𝑋EFCGHF:IIIIIIIIII < 	𝑋K@IIIII. 𝑋ABC is the 5th percentile of 𝑋K@ if  𝑋K@IIIII < 	𝑋EFCGHF:IIIIIIIIII. 𝑋A9D is the 95th percentile of 𝑋EFCGHF: if  𝑋EFCGHF:IIIIIIIIII > 	𝑋K@IIIII. 𝑋A9D is the 95th percentile of 𝑋K@ if  𝑋K@IIIII > 	𝑋EFCGHF:IIIIIIIIII. 
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Scaled value was calculated for each feature and the comparison between original and scaled 
feature is shown in the chapter 3. 
 
2.8. Feature selection 
The total features we extracted include: 82 features from MRI (gray matter volume), 82 
features from FDG-PET (SUVR), 7 features from neuropsychological tests and 3 CSF 
biomarker features. To enhance the performance of classification algorithm, we reduced the 
number of features and selected the most informative features using a method of information 
theory – information gain (IG) (Hall and Holmes, 2003; Quinlan, 2014). IG method, in our 
case, describes the amount of information gained about a feature from class separation. This 
method has successfully been used in previous studies on DTI and structural MRI for feature 
selection (Plant et al., 2010; Dyrba et al., 2013).  
Information gain is based on Shannon entropy which is a measure of unpredictability in 
information theory. When a state is unpredictable, the entropy is high. In the contrast, when a 
state is predictable, the entropy is low. In our case, the entropy of class distribution is defined 
as 𝐻(𝐶) = −∑ 𝑝(𝑐B) ∙ logST𝑝(𝑐B)U8V∈E . Where C is separated classes, 𝑐B is the ith class and 𝑝(𝑐B) is the probability of 𝑐B. Class distribution here means the distribution of separated 
classes, i.e. if C = {AD, HC} and the number of subjects in HC and AD is equal, the class 
distribution is uniform distribution. If subjects in each class is balanced, the entropy is high 
(𝐻(𝐶) = 1). On the contrary, if it is unbalanced, the entropy is relatively low. The more 
unbalanced the class size is, the lower the entropy.  
Based on entropy, information gain is defined as 𝐼𝐺(𝑓B) = 𝐻(𝐶) − 𝐻(𝐶|𝑓B), and 𝐻(𝐶|𝑓B) is 
the conditional entropy of the class distribution given the feature 𝑓B. IG describes the decrease 
in entropy of the class distribution and conditional class distribution given feature 𝑓B which 
indicates how much a feature contributes to the class separation. The range of IG value is 
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from 0 to 1. The larger the IG is, the more the information the feature gains for data 
differentiation. 
For computing conditional entropy, the feature need to be discretized if it is continuous. We 
used an algorithm based on minimum description length principle (MDLP) invented by 
Fayyad and Irani which optimizes the number and location of cut points for each feature 
(Irani and Fayyad, 1993). 
Since IG value of each feature indicates how it contributes to the class separation, to choose 
the most informative features, we only keep the features whose IG value is above the 
threshold for further classification. IG threshold varies for different modalities and different 
fold which will be described with more details in the next section. 
 
2.9. Classification 
Machine learning (ML) approaches have been used for detecting AD with imaging and non-
imaging data in the past years. The most widely used methods include Naïve Bayes, Support 
Vector Machine (SVM), and logistic regression. Naïve Bayes is a statistical method which is 
suitable for small dataset. SVM is a multivariate ML method which has advantage in high 
dimensional data classification even the data is non-linear.  Logistic regression is a generating 
model which performs very well especially with large dataset. In this study, we chose a 
univariate supervised machine learning method – Naïve Bayes classifier for the following 
reasons: Naïve Bayes performs well even with small training data (our DIAN training dataset: 
174 subjects); Compared to multivariate ML methods, it is less likely to overfit the training 
data with low - dimensional feature space (less than 200 features even before feature 
selection). Even though Naïve Bayes assumes all features used in classification which are 
mutually independent, it still works well for real-world data if the data doesn’t meet the 
condition (Eisenstein and Alemi, 1993; Dyrba et al., 2013). 
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Naïve Bayes method has been applied to predict AD progression with single and multiple 
modalities in recent studies (Plant et al., 2010; Dyrba et al., 2013; Khazaee, Ebrahimzadeh 
and Babajani-Feremi, 2016; Bhagya Shree and Sheshadri, 2018). Naïve Bayes is calculated 
based on applying Bayes’ theorem and the predictive class label is determined by posterior 
class probability (class labels in our study: e.g. HC vs. AD, converters vs. non-converters).  
Posterior class probability is defined as  𝑃(𝐶|𝐹], … , 𝐹C) where 𝐶 is class label and 𝐹 is 
selected features. Bayesian classifiers 𝑃(𝐶|𝐹], … , 𝐹C) is calculated using Bayes’ theorem: 𝑃(𝐶|𝐹], … , 𝐹C) = _( a`,…, b`|E)_(E)_( a`,…, b`) ,  where 𝑃(𝐶) is the prior probability of class,  𝑃(𝐹], … , 𝐹C) 
are the probabilities of the selected features,  𝑃(𝐹], … , 𝐹C|𝐶) are the class conditional 
probabilities.  In this study, all the features we used are continuous and follow Gaussian 
distribution (all the data were normalized described in section 2.7.1). Therefore, for each 
class, conditional probability was modeled with gaussian distribution: 𝑃(𝑓B|𝑐) =]cSdefg 𝑒𝑥𝑝 i− (jVklf)gSefg m. Each subject in the test dataset was assighed to the class with higher 
posterior probability based on the Maximum Likelihood Estimate (MLE) with training data.  
 
2.10. Two-stage cross validation 
To test the established machine learning model (training within DIAN dataset), we did two-
stage cross validation (CV): (1) At the first stage, we cross-validated with DIAN dataset (test 
dataset: DIAN) to select the best time period from the longitudinal disease progress for 
distinguishing mutation and non-mutation carriers ; (2) At the second stage, we cross-validate 
with ADNI dataset (test dataset: ADNI) to predict AD conversion in the early disease phase. 
Unlike traditional cross-validation which is usually training and testing within the same 
dataset, we did both intra- and inter- database cross validation to establish the machine 
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learning model in autosomal dominant AD and extendedly validate and apply in more 
common SAD. 
To be more specific, we firstly trained machine learning model with DIAN dataset at different 
stages of ADAD. In DIAN, the disease progression of each participant can be infered 
according to the symptom onset their parents. Estimated year of symptom onset (EYO) is 
calculated by the difference between the age of participant and parental onset of symptom for 
both mutation and non-mutation carriers (e.g. Assuming the parent started showing symptom 
at 60 and the offspring is at the age of 40 at the moment, EYO is -20 based on age difference). 
To assess the disease stage of each participant, we defined different EYO intervals for the 
analysis: (1) 15 years before symptom onset EYO = (−Inf, −15] (2) 20 to 10 years before 
symptom onset EYO = (−20,−10] (3) 15 to 5 years before symptom onset EYO =(−15,−5] (4) less than 10 years before symptom onset EYO = (−10, 0] (5) less than 5 years 
before and after symptom onset EYO = (−5, 5] (6) after symptom onset EYO = (0, Inf]. 
For the first stage cross-validation (DIAN-DIAN), we applied repeated 10-fold CV to get 
stable estimation for mutation vs. Non-mutation classification(Ojala and Garriga, 2009). 
Repeated 10-fold CV was done through the following steps: 
(1) DIAN data was randomly divided into 10 subgroups and each subgroup had same amount 
of data (subgroupi, i=1,...,10); 
(2) We used 9 subgroups as training dataset and 1 subgroup as testing dataset for each fold 
(CVi, i=1,...,10); 
(3) In each fold (CVi), the training dataset was randomly divided into 10 subgroups again; 
(4) Step 2 was repeated only within training dataset and each fold of inner loop CV is defined 
as CVij(i, j=1,...,10); 
(5) In the inner-loop CVij, Classification was done with different groups of features by using 
different IG threshold (IG percentiles from 0.5 to 0.95 with a step size of 0.05) (Dyrba et 
al., 2015); 
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(6) After 10-fold inner-loop CV (each fold was done as step 5), best features (IG threshold) 
were selected based on AUC value and applied to the testing set of CVi; 
(7) 10 fold outer-loop CV was done for CV1 ... CV10 as step 2 to step 6; 
(8) We did 10 times repeated 10 fold CV (step 1 to step 7 was repeated 10 times).  
After the first stage CV, established machine learning model and selected features were taken 
forward to the second stage validation to classify HC vs. AD and converter vs. Non-converter. 
For the second stage cross-validation (DIAN-ADNI), we applied repeated hold-out CV 
instead of 10-fold CV. Repeated hold-out CV was done through the following steps:  
(1) Data and results from 1st stage CV were prepared; 
(2) ADNI data was randomly divided into 10 subgroups and each subgroup had same amount 
of data (subgroupi, i=1,...,10); 
(3) We used 1 subgroup as testing dataset for each validation (CVi, i=1,...,10); 
(4) Training model of DIAN was applied to ADNI testing dataset (subgroupi) for CVi; 
(5) 10 times CV was done for CV1 ... CV10 as step 4; 
(6) We did 10 times repeated hold-out CV (step 2 to step 5 was repeated 10 times). 
For traditional 10-fold CV we used in the first stage, testing dataset in one fold will be part of 
the training dataset in another fold. In the second stage, we used hold-out CV because training 
and testing data are independent. Considering limited number of subjects in DIAN, we did 
repeated 10-fold CV to get stable estimation. For consistency, CV in the second stage was 
also repeated the same times. Two-stage CV schema is illustrated in Figure 7. 
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Figure 7. Cross-validation schema for feature selection and classification. Within each cross-validation 
fold (CVi), another loop of cross-validation was run on the training data to estimate the best IG threshold 
for feature selection. The best threshold of that inner loop was the applied to the test sample of that fold 
(CVi). This was run for all CV folds to determine the overall best set of features for the prediction of MC vs 
NC in the DIAN data. The best feature set was subsequently used as predictors tested in ADNI via Naïve 
Bayes, where classification result is reported as the average AUC across the repeated cross-validation. 
 
2.11. Evaluation 
To evaluate the classification result, we report the receiver operating characteristic (ROC) 
curve, area under the curve (AUC), sensitivity and specificity.  
ROC curve and AUC are usually used to evaluate the performance of binary classifier. ROC 
curve is created by different thresholds and plotted with true positive rate (TPR) and false 
positive rate (FPR). TPR is defined as  v_v_w`? and FPR is defined as `_v?w`_, where 𝑇𝑃 is the 
number of instances correctly identified as positive class,  𝑇𝑁 is the number of instances 
correctly identified as negative class, 𝐹𝑃 is the number of instances incorrectly identified as 
positive class which belong to negative class, 𝐹𝑁 is the number of instances incorrectly 
identified as negative class which belong to positive class. If FPR=0 and TPR=1, it means the 
classifier is perfect and all the instances are correctly classified. If ROC curve is plotted as 𝑦 = 𝑥, it means the classifier randomly classified the instances. Therefore, the closer the ROC 
points to the (0,1) point, the better the classifier is. AUC is the area under the ROC curve. 
Since the ROC curve is usually above the diagonal (𝑦 = 𝑥), the AUC value is between 0.5 to 
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1. Higher AUC value indicates better performance of classifier. ROC curve and AUC are 
illustrated in Figure 8. A big advantage of AUC is insensitivity to the data imbalance. Hence, 
we used AUC as a measure of classification result instead of accuracy (e.g. Assuming 90% 
samples belongs to the positive class and all the samples are classified as positive class, it’s 
not a good classifier even with the accuracy of 90%).  In our case, the samples in converter 
group are less than that in non-converter group of ADNI (HC converter/non-converter, 
n=18/74; MCI converter/non-converter, n=81/208). Furthermore, we also reported sensitivity 
and specificity as the classification result. The definition of sensitivity is the same as TPR. 
For the specificity, it equals to 1-FPR. All the measures (AUC, sensitivity and specificity) 
were averaged across multiple CV and with 95% confidence intervals reported.  
 
Figure 8. Example of ROC curve. The area colored in grey is area under the ROC curve. 
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2.12. Statistics 
Demographic differences between groups were compared using two-sample t-test for 
continuous data and  𝜒S test for categorical data (mutation vs. non-mutation carriers, HC vs. 
AD, HC converter vs. HC non-converter, MCI converter vs. MCI non-converter).  
In the two-stage cross validation, two-sample t-tests were applied to compare the AUC 
between different modality combination (e.g. single modality vs. two-modality, two-modality 
vs. three modality and so on). In the first-stage CV, we did t-tests for the classification result 
of mutation vs. non-mutation carriers in DIAN and selected the best single or multiple-
modality combination for the second-stage CV. In the second stage, t-tests were applied to 
HC vs. AD, converters vs. non-converters to compare single and multi-modality classification 
results. P<0.05 was defined as statistical significance. 
 
2.13. Software and toolbox 
Data preprocessing (normalization and standardization) were done in Python 3.6 (Spyder IDE 
3.2.4). Box-cox transformation was done with SciPy library. Feature selection and 
classification were processed in Eclipse Java IDE (version 4.5.1) using free Weka toolbox 
(https://www.cs.waikato.ac.nz/ml/weka/). For statistical and other analysis, we conducted in 
R Statistical Computing Environment (version 1.1.414) and Matlab (version 2015b). 
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3 Results 
 
3.1. Preprocessed features 
We did a two-step preprocessing (normalization and standardization) for each feature of MRI, 
FDG-PET, neuropsychological tests and CSF biomarkers. Due to a large number of total 
features (N=174), we only included CSF features (Ab1-42, total Tau, p-tau, N=3) as examples 
to show the results of preprocessing.  
We applied normalization as the first step of preprocessing using Box-Cox transformation to 
all features of all modalities. For illustrational purposes, the distribution and Quantile-
Quantile plot (QQ plot) before and after normalization are shown for CSF Ab1-42, total 
Tau ,and pTau from DIAN and ADNI (Figure 9 and Figure 10). For DIAN, parameters 𝜆 of 
Box-Cox transformation was estimated for Ab, Tau and p-Tau respectively: 𝜆|} =0.436, 	𝜆 = −0.122, 𝜆 = −0.496. For ADNI dataset, estimated parameter λ were: 𝜆|} = 0.437, 	𝜆 = −0.216, 𝜆 = −0.281. The results in Figure 9 and Figure 10 show 
that features become more normally distributed where points in QQ-plot become closer to the 
reference line after Box-Cox transformation. All CSF features are unimodally distributed 
except Ab of ADNI which is from bimodal distribution. Due to technical limitations, 
amyloid-b42 CSF immunoassay was truncated to 1700 pg/mL in ADNI. 
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Figure 9. Histogram and normal QQ plot of DIAN CSF biomarkers. Data distribution of (A) Aβ, (D) Tau 
and (G) p-tau with and without normalization are shown together for comparison. QQ plots for (B, C) Aβ, 
(E, F) Tau and (H, I) p-tau are plotted against quantiles from a normal distribution (blue: non-normalized 
data, red: normalized data). 
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Figure 10. Histogram and normal QQ plot of ADNI CSF biomarkers. Data distribution of (A) Aβ, (D) Tau 
and (G) p-tau with and without normalization are shown together for comparison. QQ plots for (B, C) Aβ, 
(E, F) Tau and (H, I) p-tau are plotted against quantiles from a normal distribution (blue: non-normalized 
data, red: normalized data). 
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After the Box-Cox transformation, Centiloid scaling method was applied to the transformed 
data. Figure 11 shows the CSF data before and after normalization and standardization for 
both DIAN and ADNI. Before preprocessing, CSF Ab, Tau and pTau of DIAN and ADNI 
show different data ranges and all CSF data is significantly different between two datasets 
(p < 0.001) (Figure 11A). After preprocessing, all CSF features were converted to the similar 
ranges and there is no significant difference between two datasets (𝑝K = 0.060, 𝑝v9 =0.761, 𝑝v9 = 0.150)  (Figure 11B).  
 
Figure 11. Box plot of CSF data for the group comparison (ADNI vs DIAN) (A) before and (B) after 
normalization and standardization. The top represents the 75th percentile of the data and the bottom is the 
25th percentile of the data. The horizontal line in the middle is the median (50th percentile). 
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3.2. Establishing machine learning model within DIAN 
To establish the machine learning model, we first selected the most informative features  
of MRI, FDG-PET, neuropsychological data and CSF biomarker respectively based on 
information gain method. With selected features, we applied the Naïve Bayes method to 
differentiate mutation and non-mutation carriers. 
3.2.1 Feature selection across EYO 
In DIAN, the subjects were categorized in different 10-year EYO intervals. We did feature 
selection and classification for each EYO interval sequentially. For the cross-validation, we 
did repeated (10 times) 10-fold CV which has been described in details in the method part. 
The selected features whose IG values were above the thresholds in more than half CV folds 
(larger than the IG threshold in more than 10*10/2 folds) were shown in Figure 12 to Figure 
15. 
Using MRI, selected features for differentiating mutation carriers and non-carriers at more 
than 15 years before the onset of symptoms were mainly in the central of left hemisphere: left 
paracentral lobule and postcentral gyrus (Figure 12A). By EYO = (−20,−10], selected 
features of grey matter volumes were left putamen and right lingual (Figure 12B). ROIs from 
the central regions in both medial and lateral sides (left paracentral lobule and postcentral 
gyrus, right supramarginal gyrus) were selected at the EYO = (−15,−5] (Figure 12C). At the 
EYO interval (−10, 0], right accumbens and precuneus were selected as the most informative 
features (Figure 12D). By EYO = (−5, 5] which is around the year of symptom onset, more 
features were selected including left putamen, left and right hippocampus, right banks of the 
superior temporal sulcus, right cuneus and precuneus (Figure 12E). At the years after 
symptom onset, similar features as (−5, 5] were selected: left and right hippocampus, left 
amygdala, left and right postcentral gyrus, right cuneus (Figure 12F). From the years 
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approaching symptom onset to years after the onset, selected features of GM volumes for 
classification were mostly memory-related such as hippocampus and precuneus. 
Using FDG-PET, selected features at more than 15 years before the onset of symptoms were 
left caudal anterior cingulate cortex, right fusiform and superior parietal cortex (Figure 13A). 
By EYO = (−20,−10], selected features of FDG-PET were left and right hippocampus, left 
amygdala and right frontal pole (Figure 13B). Three ROIs from the right hemisphere 
(pallidum, hippocampus, and accumbens) were selected at the EYO = (−15,−5] (Figure 
13C). At the EYO interval (−10, 0], left inferior parietal, right cuneus, and isthmus-cingulate 
cortex were selected as the most informative features (Figure 13D). By EYO = (−5, 5] which 
is around the year of symptom onset, features were selected including left and right 
precuneus, right isthmus-cingulate cortex (Figure 13E). In the years after symptom onset, 
more features were selected: left inferior and superior parietal cortex, left and right isthmus-
cingulate cortex, right precuneus (Figure 13F). From the years approaching symptom onset to 
years after the onset, selected features of FDG-PET for classification were mostly memory-
related such as parietal and cingulate cortex. 
Using the data of neuropsychological tests, selected features at more than 15 years before the 
onset of symptoms were mainly related to semantic and episodic memory: Boston Naming 
Test, Animal Fluency Test and Word List Delayed Recall. For EYO = (−20,−10], selected 
features of neuropsychological data were Boston Naming Test, Animal Fluency Test and 
Word List Immediate Recall. Features related to executive function (Animal Fluency Test, 
Trail Making Test (A&B)) were selected at the EYO = (−15,−5]. At the EYO interval (−10, 0], Boston Naming Test, Animal Fluency Test, and MMSE were selected as the most 
informative features. By EYO = (−5, 5] which is around the year of symptom onset, features 
were selected including Boston Naming Test, Trail Making Test (A), Word List Delayed, and 
Immediate Recall. At the years after symptom onset, three features were selected: Boston 
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Naming Test and Trail Making Test (A&B). Neuropsychological features of different EYO 
intervals are shown in Figure 14. 
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Figure 12. Desikan-Killiany atlas of selected MRI features at different EYO intervals: (A)	(−𝐼𝑛𝑓,−15] 
(B)	(−20,−10] (C)	(−15,−5]	 (D)	(−10, 0] (E)	(−5, 5] (F)	(0, 𝐼𝑛𝑓). 
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Figure 13. Desikan-Killiany atlas of selected FDG-PET features at different EYO intervals: 
(A)	(−𝐼𝑛𝑓,−15] (B)	(−20,−10] (C)	(−15,−5]	 (D)	(−10, 0] (E)	(−5, 5] (F)	(0, 𝐼𝑛𝑓). 
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Figure 14. Selected neuropsycholocal features acrosst different EYO intervals 
 
Using CSF biomarkers, selected feature at more than 15 years before the onset of symptoms 
was pTau. By EYO = (−20,−10], the selected feature of CSF biomarkers was pTau which is 
the same as earlier EYO interval. Ab and pTau were selected at the EYO = (−15,−5]. At the 
EYO interval (−10, 0], Ab and pTau were selected as the most informative features. By EYO = (−5, 5] which is around the year of symptom onset, the selected feature was pTau. At 
the years after symptom onset, two features were selected: Ab and pTau. From the very early 
years before symptom onset, pTau was shown as an informative feature for differentiating 
mutation carriers and non-carriers until the years after symptom onset which indicates pTau is 
a prominent biomarker for the early diagnosis of AD. CSF features of different EYO intervals 
are shown in Figure 15. 
 
 
Figure 15. Selected CSF features at different EYO intervals 
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3.2.2 Classification of ADAD for different EYO intervals 
With selected features described in 3.2.1, the classification was done using Naïve Bayes 
method for the separation between mutation and non-mutation carriers with single and 
multiple modalities across different EYO intervals. The results of the cross-validation are 
shown in Figure 16, Table 9 and Table 10. In general, classification results within DIAN 
became better when the time gets closer to the symptom onset.  
The classification results (AUC) of single modality are shown in Figure 16A.  For MRI, AUC 
generally increased across EYO intervals (except the EYO interval (−10, 0] which was a bit 
decreased comparing to (−15,−5]). AUC became larger than 85% (AUC = 90.00%) at the 
EYO interval [0, +Inf). For FDG-PET, AUC increased across EYO intervals from the EYO 
interval of (−20,−10]. From the EYO interval of (−5, 5], the AUCs of FDG-PET were 
better than the AUCs of MRI and AUC achieved higher than 85% (AUC = 89.50, 92.25%). 
For neuropsychological data, AUC increased across EYO intervals across all the EYO 
intervals and approached 85% at the EYO of (−10, 0] (AUC = 84.11%). From the EYO 
interval of (−10, 0], the AUCs of psychological data were better than the AUCs of MRI. For 
CSF, AUC increased across EYO intervals from the EYO interval of (−15,−5] and reached 
89.17% at (−10, 0] (>85%). The AUCs of CSF biomarkers were larger than the other single 
modality across most time intervals (except the EYO interval (−15,−5] which was lower 
than MRI). Across all EYO intervals, highest AUC was observed for CSF (97.75% at (0, +𝐼𝑛𝑓)). 
The classification results (AUC) of two modality combinations are shown in Figure 16B. For 
MRI-FDG (M-F), AUCs were higher than both MRI and FDG-PET across most of the EYO 
intervals except (−15,−5]. For MRI-PSY (M-P), AUCs were higher than both MRI and 
neuropsychology across most of the EYO intervals except (−20,−10]. For MRI-CSF (M-C), 
AUCs were higher than both MRI and CSF across most of the EYO intervals except (−5, 5]. 
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The AUC of M-C became clinical relevent from (−20,−10] (AUC = 91.67%) which was 
earlier than every single modality. For FDG-PSY (F-P), AUCs were higher than both FDG-
PET and neuropsychology across most of the EYO intervals except (0, +𝐼𝑛𝑓). For FDG-CSF 
(F-C), AUCs were higher than both FDG-PET and CSF across most of the EYO intervals 
except (−10, 0] and (−5, 5] where CSF had higher AUC values. For PSY-CSF (P-C), AUCs 
were not higher than CSF at (−𝐼𝑛𝑓,−15], (−20,−10], (−15,−5] and (−5, 5]. 
The classification results (AUC) of three and four (all) modality combinations are shown in 
Figure 16C. For MRI-FDG-PSY (M-F-P), AUCs were higher than every single one of these 
three modalities across all of EYO intervals but not higher than all two modality combinations 
from these three modalities. For MRI-FDG-CSF (M-F-C), AUCs were higher than almost 
every single one of these three modalities across all of EYO intervals except CSF of (−5, 5] 
and not higher than all two modality combinations from these three modalities. For MRI-
PSY-CSF (M-P-C), AUCs were higher than every single one of these three modalities across 
all of EYO intervals and equal or higher than most two modality combinations from these 
three modalities (except M-C of (−20,−10]). For FDG-PSY-CSF (F-P-C), AUCs were 
higher than most single ones across all of EYO intervals except CSF of (−20,−10] and (−15,−5], but not higher than all two modality combinations from these three modalities. 
Combining all four modalities, the results showed that AUCs of all-modality-combination 
were higher than every single modality across all of EYO intervals. However, compared to 
two and three modality combinations, all modality combinations did not improve 
classification results for all EYO intervals. 
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Figure 16.  AUC for the discrimination of mutation carriers vs. non-mutation carriers of (A) single 
modality (B) two-modality combination (C) three-modality and all combination across different EYO 
intervals.  
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Table 9: AUC(95%CI) for the discrimination of mutation carriers vs. non-mutation carriers of single 
modality, two-modality combination, three-modality and all combination across different EYO intervals 
Modality/
Modalities 
Classification results (AUC) of different EYO intervals  
(-Inf, -15)  [-20, -10)  [-15, -5)  [-10, 0)  [-5, 5)  [0, +Inf)  
MRI 66.58±2.60  78.25±2.50  83.50±2.26  82.22±1.71  84.75±1.80  90.00±1.67  
FDG 68.33±2.88  65.50±2.86  73.92±2.66  78.32±2.15  89.50±1.50  92.25±1.33  
PSY 55.79±3.11  58.92±2.68  71.79±2.63  84.11±1.93  87.81±1.62  93.79±1.20  
CSF 72.67±2.42  81.42±2.07  80.29±2.52  89.17±1.25  95.88±0.98  97.75±0.76  
M-F 77.17±2.34  81.17±2.34  82.67±2.14  82.83±1.99  90.63±1.30  97.00±0.86  
M-P 72.67±2.60  75.83±2.31  84.75±2.08  89.01±1.52  92.25±1.49  96.67±0.91  
M-C 76.00±2.48  91.67±1.22  91.00±1.66  92.81±1.19  93.50±1.16  98.33±0.69  
F-P 70.75±2.76  70.50±2.51  74.92±2.64  85.86±1.84  92.50±1.27  93.42±1.16  
F-C 74.33±2.68  82.50±1.90  81.67±2.44  87.25±1.54  95.13±0.87  99.25±0.38  
P-C 67.08±2.70  74.00±2.16  77.42±2.61  94.79±0.89  95.63±0.89  99.08±0.47  
M-F-P 80.83±2.25  80.00±2.15  85.00±2.09  86.99±1.77  93.75±1.13  97.00±0.89  
M-F-C 84.33±1.95  88.17±1.63  88.17±1.90  91.11±1.33  94.63±0.91  99.67±0.23  
M-P-C 78.25±2.54  86.67±1.61  91.00±1.80  95.65±0.96  96.13±0.81  99.08±0.47  
F-P-C 74.08±2.60  78.83±1.95  79.42±2.58  92.58±1.22  96.88±0.67  99.58±0.30  
M-F-P-C 83.83±2.05  85.00±1.76  89.75±1.82  93.31±1.23  97.38±0.62  99.58±0.30  
For each modality or modality combination, the average AUC with SE of repeated cross-validation is 
presented. Abbreviations: M-F = MRI & FDG; M-P = MRI & PSY; M-C = MRI & CSF; F-P = FDG & 
PSY; F-C = FDG & CSF; P-C = PSY & CSF; M-F-P = MRI & FDG &PSY; M-F-C = MRI & FDG & 
CSF; M-P-C = MRI & PSY & CSF; F-P-C = FDG &PSY & CSF; M-F-P-C = MRI & FDG &PSY & CSF. 
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Table 9: Sensitivity and specificity for the discrimination of mutation carriers vs. non-mutation carriers of 
single modality, two-modality combination, three-modality and all combination across different EYO 
intervals 
Modality/
Modalities 
Classification results (sensitivity, specificity) of different EYO intervals  
(-Inf, -15)  [-20, -10)  [-15, -5)  [-10, 0)  [-5, 5)  [0, +Inf)  
MRI 85.33, 60.00 83.33, 75.17 93.33, 74,17 90.00, 68.33 90.25, 85.50 91.75, 93.50 
FDG 88.33, 62,50 88.67, 59.67 93.33, 64.33 90.00, 59.17 92.00, 90.50 95.75, 82.00 
PSY 85.33, 47.00 87.00, 48.17 93.33, 58.83 90.00, 70.17 90.00, 90.50 96.25, 82.50 
CSF 88.33, 62.50 91.33, 73.33 94.67, 74.00 90.00, 82.50 95.50, 95.00 96.83, 98.50 
M-F 83.33, 72.50 83.33, 75.67 93.33, 72.67 90.00, 68.83 92.00, 91.50 95.75, 93.00 
M-P 83.33, 66.00 83.33, 71.50 93.33, 77.33 92.08, 91.17 93.50, 94.50 95.83, 99.00 
M-C 83.33, 72.00 94.67, 89.83 98.00, 86.50 92.25, 96.00 95.50, 94.50 98.33, 98.50 
F-P 83.33, 63.50 83.33, 63.00 93.33, 65.00 90.50, 86.83 92.50, 96.00 96.75, 84.50 
F-C 83.33, 68.50 83.33, 76.33 93.33, 75.50 90.17, 90.17 94.25, 96.00 98.75, 100 
P-C 83.33, 57.50 83.67, 67.17 93.33, 69.50 92.67, 98.67 95.25, 98.00 99.08, 99.50 
M-F-P 83.33, 77.00 83.33, 74.33 93.33, 76.17 90.00, 75.00 93.75, 96.00 96.75, 93.00 
M-F-C 83.33, 81.50 83.33, 85.83 93.33, 82.17 90.25, 82.50 94.50, 96.00 96.00, 99.00 
M-P-C 83.33, 75.00 83.33, 83.50 93.33, 88.33 90.00, 90.67 94.75, 99.00 96.75, 98.50 
F-P-C 83.33, 68.00 83.33, 73.83 93.33, 72.17 90.00, 84.83 96.00, 98.00 97.00, 99.50 
M-F-P-C 83.33, 81.00 83.33, 81.17 93.33, 85.00 90.25, 85.83 96.75, 98.00 97.00, 99.50 
For each modality or modality combination, the average sensitivity and specificity of repeated cross-
validation is presented. Abbreviations: M-F = MRI & FDG; M-P = MRI & PSY; M-C = MRI & CSF; F-P 
= FDG & PSY; F-C = FDG & CSF; P-C = PSY & CSF; M-F-P = MRI & FDG &PSY; M-F-C = MRI & 
FDG & CSF; M-P-C = MRI & PSY & CSF; F-P-C = FDG &PSY & CSF; M-F-P-C = MRI & FDG &PSY 
& CSF. 
 
  
 
 
53 
3.2.3 Optimal classification model of DIAN 
Before further cross-validation in ADNI, we selected the prediction model from classification 
models of different EYO intervals. Based on the classification results and sample size, we 
selected the machine learning model trained for EYO interval (−5,+𝐼𝑛𝑓) because 1) the 
classification result for mutation vs. non-mutation carriers was within the clinical relevant 
accuracy (AUC > 85%) and 2) the classification model was established to predict the early 
stage of AD and 3) sufficient sample size compared to one EYO interval. 
For the EYO interval of (−5,+𝐼𝑛𝑓), we also did feature selection using information gain 
(IG) method. For MRI, the selected features included left and right hippocampus, left 
putamen and amygdala, right precuneus, right postcentral gyrus, and cuneus. The average IG 
value of all ROI features (41 ROIs for each hemisphere) and MRI features after selection are 
shown in Figure 17. 
For FDG-PET, the selected ROI features were predominantly located within posterior parietal 
cortex of the default mode network including left inferior and superior parietal cortex, left and 
right isthmus-cingulate cortex, left and right precuneus. The average IG value of all ROI 
features and selected FDG-PET features are shown in Figure 18. 
For neuropsychological tests, the most discriminative features were Boston Naming Test, 
Trail Making Test (A&B) and Word List Immediate Recall. For CSF biomarkers, Ab and 
pTau were selected as the most informative features. The average IG value of all 
neuropsychological and CSF features before and after selection are shown in Figure 19. 
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Figure 17. (A) Bar graph of mean IG value for each MRI feature (selected features were colored with 
orange for the left hemisphere and red for the right hemisphere). (B)Selected MRI features from Desikan-
Killiany atlas at the EYO interval of  (−5,+𝐼𝑛𝑓). 
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Figure 18.  (A) Bar graph of mean IG value for each FDG-PET feature (selected features were colored 
with orange for the left hemisphere and red for the right hemisphere). (B)Selected FDG-PET features from 
Desikan-Killiany atlas at the EYO interval of  (−5,+𝐼𝑛𝑓). 
 
 
56 
 
Figure 19.  Bar graph of mean IG value for each PSY and CSF feature (selected features were colored 
with red) at the EYO interval of  (−5,+𝐼𝑛𝑓). 
 
Classification results of single and multiple modalities for distinguishing mutation and non-
mutation carriers at the EYO interval of (−5,+𝐼𝑛𝑓) are shown in Figure 20 and Table 10. 
For the single modality, the best classification result was using CSF biomarkers with the AUC 
of 93.75%. Concatenating features from two modalities, the best performance was combining 
neuropsychological data and CSF biomarkers which was significantly better than every single 
modality. Besides PSY-CSF, the AUC of FDG-CSF was also significantly improved 
compared to every single modality. For the rest two-modality combinations (MRI-FDG, MRI-
PSY, FDG-PSY, MRI-CSF), classification results were significantly better than the single 
modality of MRI and FDG-PET, but not better than PSY or CSF. The best combination 
among three-modality combinations was FDG-PSY-CSF, which was significantly better than 
the all two-modality combinations except PSY-CSF. Other than that, the AUC of MRI-PSY-
CSF was significantly higher than MRI-FDG, MRI-PSY, FDG-PSY, and MRI-CSF. MRI-
FDG-PSY performed significantly better than MRI-FDG, MRI-PSY, and FDG-PSY. 
However, the result of three-modality MRI-FDG-CSF didn’t improve significantly from any 
two-modality combination. Combining all four modalities, the AUC was significantly better 
than all three-modality combinations except FDG-PSY-CSF. 
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Table 10: Mean AUC, sensitivity and specificity for the discrimination of mutation carriers vs. non-
mutation carriers of single modality, two-modality combination, three-modality and all combination at the 
EYO interval of  (−5,+𝐼𝑛𝑓). 
Modality/ 
Modalities 
Classification results of EYO interval  (−𝟓,+𝑰𝒏𝒇) 
Mean AUC (95%CI) Sensitivity, Specificity 
MRI 86.38 (84.06, 88.70) 85.97, 80.50 
FDG 90.07 (88.02, 92.12) 88.50, 88.08 
PSY 93.61 (92.05, 95.17) 91.03, 91.58 
CSF 93.75 (91.91, 95.59) 92.53, 95.00 
M-F 92.54 (90.71, 94.37) 89.80, 92.92 
M-P 94.19 (92.54, 95.84) 91.33, 93.42 
M-C 95.24 (93.94, 96.54) 92.53, 97.08 
F-P 94.87 (93.33, 96.41) 92.40, 95.25 
F-C 95.97 (94.62, 97.32) 93.53, 97.08 
P-C 96.92 (95.67, 98.17) 95.47, 98.33 
M-F-P 96.25 (94.83, 97.67) 94.37, 95.17 
M-F-C 95.93 (94.62, 97.24) 93.23, 97.67 
M-P-C 97.03 (95.96, 98.10) 94.50, 98.75 
F-P-C 98.08 (97.23, 98.93) 96.07, 98.75 
M-F-P-C 98.18 (97.29, 99.07) 96.67, 99.67 
 
Figure 20. AUC of single and multiple modalities (classification of mutation carriers and non-mutation 
carriers). The significant increasing of AUC is only marked for the highest one (e.g. The AUC of combining 
psychological data with CSF biomarkers is significantly higher than any single modality and it is only marked 
with the modality with highest AUC: CSF biomarkers). 
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3.3. Cross-validation in ADNI 
With the machine learning model trained in DIAN, we further applied to the ADNI dataset to 
validate in the more common SAD. Classification models of every single modality (MRI, 
FDG, PSY, CSF) and the multi-modality combinations with best results were used in ADNI 
dataset. 
 
3.3.1 Discrimination between HC and AD in ADNI 
We used three single modality models (MRI, FDG, CSF), the two-modality combination 
(FDG-CSF) and the three-modality combination (MRI-FDG-CSF) models with the best 
performance in DIAN to further apply to the ADNI dataset. Note that neuropsychological data 
was not used for discriminating HC versus AD since it provided diagnostic information which 
may lead to circularity. The ROC curves and classification results (AUC, sensitivity and 
specificity) of single- and multi- modality are shown in Figure 21 and Table 11. Among the 
single modality models, the FDG-PET model had the best result (AUC = 91.96%). The two-
modality combination FDG-CSF (best two-modality model in DIAN), achieved AUC of 
94.80%. The three-modality combination MRI-FDG-CSF showed AUC of 96.00%.  
In comparison with each single modality model, FDG-CSF performed significantly better. 
The three-modality MRI-FDG-CSF even had significantly higher AUC than FDG-CSF 
model. In general, MRI-FDG-CSF showed the best result among all single- and multi- 
modality models. 
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A          B 
Figure 21. Classification result for HC versus AD in SAD based on ADAD Naïve Bayes model with MR 
volume, FDG-PET and CSF biomarkers and the multi-modalities combination with best performance in 
ADAD. (a) ROC curves of classification: HC vs. AD. (b) AUC of classification: HC vs. AD. The significant 
increasing of AUC is only marked for the highest one. AUC of F-C and M-F-C is significant lager than 
FDG-PET and it is also significant larger than MRI and CSF (AUC: FDG > CSF > MRI) 
 
Table 11: Classification result (AUC, sensitivity and specificity) for HC versus AD of ADNI data with 
single modality and corresponding best multi-modality combination tested in DIAN. 
Modality/Modalities Mean AUC (95%CI) Sensitivity, Specificity 
MRI  86.17 (85.94, 86.40) 83.11, 77.81 
FDG 91.69 (91.55, 91.82) 83.38, 88.12 
CSF 90.81 (90.66, 90.96) 84.00, 87.91 
F-C 94.80 (94.69, 94.90) 89,11, 90.62 
M-F-C 96.00 (95.89, 96.11) 93.35, 91.40 
 
3.3.2 Classification of HC converters and non-converters in ADNI 
We used all single modality models (MRI, FDG, PSY, CSF), the two-modality combination 
(PSY-CSF) and the three-modality combination (FDG-PSY-CSF) models with the best 
performance in DIAN, and all-modality combination model (MRI-FDG-PSY-CSF) to 
distinguish HC converters and non-converters of ADNI dataset. The ROC curves and 
classification results (AUC, sensitivity, and specificity) of single- and multi- modality are 
shown in Figure 22 and Table 12. Among the single modality models, the neuropsychological 
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model had the best result (AUC = 68.17%), and CSF model (best single model in DIAN) 
showed the AUC of 49.57% which was not better than the other single modalities. The two-
modality combination PSY-CSF (best two-modality model in DIAN), achieved AUC of 
58.22%. The three-modality combination FDG-PSY-CSF (best three-modality model 
established in DIAN), showed AUC of 63.28%. All-modality combination (MRI-FDG-PSY-
CSF) achieved AUC of 62.69%. 
Compared with each single modality model, FDG-CSF performed only significantly better 
than CSF model. The three-modality FDG-PSY-CSF showed significantly higher AUC than 
PSY-CSF model as well as FDG and CSF single-modality models. Four-modality-
combination didn’t show better performance compared to three- modality model. 
 
A          B 
Figure 22. Classification result for HC Converters (HC-C) versus HC non-Converters (HC-NC) in SAD 
based on ADAD Naïve Bayes model with all four modalities: MR volume, FDG-PET, Psychological data 
and CSF biomarkers and the multi-modality combinations with best performance in ADAD. (a) ROC 
curves of classification: HC-C vs. HC-NC. (b) AUC of classification: HC-C vs. HC-NC. The significant 
increasing of AUC is only marked for the highest one. (AUC: PSY > MRI > FDG >CSF) 
HC-C = HC Converters; HC-NC = HC Non-Converters 
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Table 12: Classification result (AUC, sensitivity and specificity) for HC-C versus HC-NC of ADNI data 
with single modality and corresponding best multi-modality combination tested in DIAN. 
Modality/Modalities Mean AUC (95%CI) Sensitivity, Specificity 
MRI  64.65 (64.03, 65.27) 84.10, 52.05 
FDG 62.79 (62.24, 63.35) 84.10, 34.46 
PSY 68.17 (67.68, 68.67) 84.10, 61.00 
CSF 49.57 (48.95, 50.19) 84.10, 10.67 
P-C 58.22 (57.64, 58.79) 84.10, 22.49 
F-P-C 63.28 (62.75, 63.82) 84.10, 35.13 
M-F-P-C 62.69 (62.12, 63.26) 84.10, 36.06 
 
 
3.3.3 Classification of MCI converters and non-converters in 
ADNI 
We used all single modality models (MRI, FDG, PSY, CSF), the two-modality combination 
(PSY-CSF) and the three-modality combination (FDG-PSY-CSF) models with the best 
performance in DIAN, and all-modality combination model (MRI-FDG-PSY-CSF) to 
distinguish MCI converters and non-converters of ADNI dataset. The ROC curves and 
classification results (AUC, sensitivity, and specificity) of single- and multi- modality are 
shown in Figure 23 and Table 13. Among the single modality models, the neuropsychological 
model had the best result (AUC = 83.24%), and CSF model (the best single model in DIAN) 
showed the AUC of 82.61% which was not better than the other single modalities. The two-
modality combination PSY-CSF (best two-modality model in DIAN), achieved AUC of 
88.38%. The three-modality combination FDG-PSY-CSF (best three-modality model 
established in DIAN), showed AUC of 89.12%. All-modality combination (MRI-FDG-PSY-
CSF) achieved AUC of 88.66%. 
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Compared with each single modality model, FDG-CSF model had significantly better 
performance. The three-modality FDG-PSY-CSF showed significantly higher AUC than 
PSY-CSF model as well as all single-modality models. Four-modality-combination performed 
significantly better than all single-modality models but not better than two- and three- 
modality models. 
 
A          B 
Figure 23. Classification result for MCI Converters (MCI-C) versus MCI non-Converters (MCI-NC) in 
SAD based on ADAD Naïve Bayes model with all four modalities: MR volume, FDG-PET, Psychological 
data and CSF biomarkers and the multi-modality combinations with best performance in ADAD. (a) ROC 
curves of classification: MCI-C vs. MC-NC. (b) AUC of classification: MCI-C vs. MCI-NC. The significant 
increasing of AUC is only marked for the highest one. (AUC: Psy >CSF > FDG-PET > MRI) 
MCI-C = MCI Converters; MCI-NC = MCI Non-Converters 
 
Table 13: Classification result (AUC, sensitivity and specificity) for MCI-C versus MCI-NC of ADNI data 
with single modality and corresponding best multi-modality combination tested in DIAN. 
Modality/Modalities Mean AUC (95%CI) Sensitivity, Specificity 
MRI  72.41 (72.20, 72.63) 81.88, 53.76 
FDG 75.56 (75.33, 75.79) 81.05, 54.83 
PSY 83.24 (83.04, 83.44) 81.57, 69.92 
CSF 82.61 (82.42, 82.80) 81.80, 76.06 
P-C 88.38 (88.24, 88.52) 83.25, 76.99 
F-P-C 89.12 (88.97, 89.28) 82.79, 82.42 
M-F-P-C 88.66 (88.51, 88.80) 83.48, 80.92 
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3.3.4 Overview of results in ADNI 
In general, the combinations of multiple modalities improved the classification result 
especially when the single modality performed relatively good (such as HC vs. AD, MCI 
converters vs. non-converters).  
With the best models established in DIAN, classification results of ADNI were shown in 
Figure 24 and Table 14. For the most difficult task, the AUC of distinguishing HC converter 
and non-converters was 62.69% using all four modalities. For predicting MCI conversion, the 
four-modality combination model showed AUC of 88.66%. To distinguish HC and AD, the 
best model in DIAN (FDG-CSF) achieved AUC of 94.80%. 
 
Figure 24. Classification result (AUC) for all three pairs of groups of ADNI data with corresponding best 
multi-modality combination tested in DIAN. 
 
Table 14: Classification result (AUC, sensitivity and specificity) for all three pairs of groups of ADNI data 
with corresponding best multi-modality combination tested in DIAN. 
Groups Mean AUC (95%CI) Sensitivity, Specificity Best combinations in DIAN 
HC Cov vs. nCov  62.69 (62.12, 63.26) 84.10, 36.06 MRI-FDG-PSY-CSF 
MCI Cov vs. nCov  88.66 (88.51, 88.80) 83.48, 80.92 MRI-FDG-PSY-CSF 
HC vs. AD 94.80 (94.69, 94.90) 89,11, 90.62 FDG-CSF 
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4 Discussion 
 
In this study, we used Bayesian machine learning method: 1) to differentiate mutation and 
non-mutation carriers in ADAD and 2) to detect subjects at early risk-stages of SAD (HC to 
MCI/AD or MCI to AD converters ) 
For the classification of ADAD mutation and non-mutation carriers in the training sample 
(DIAN), the result showed that the classification accuracy increased with the progress of the 
disease (higher EYO). When combining multiple modalities, it achieved higher classification 
accuracy than a single modality. Moreover, classification with three-modality combination 
showed a better result than two-modality combination and combination of all the modalities 
showed the best result.   
To predict the conversion in the early stage of SAD, we applied the same machine learning 
model established in DIAN (ADAD subjects). For predicting the conversion from MCI to 
AD, classification results achieved clinically relevant levels of accuracy when combining two 
or more modalities. Combinations of multiple modalities significantly improved the 
performance of the classifiers compared to single modality for distinguishing MCI converters 
and non-converters. For the more difficult task, predicting conversion from HC to MCI, the 
classification accuracy didn’t achieve clinically relevant levels of accuracy. 
For the discrimination between HC and AD, the same classification model establish in DIAN 
was applied.  The AUC score ranged from 86% to 95% (sensitivity: 83% - 93%, specificity: 
78% - 91%), supporting the plausibility of the established machine learning model. 
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4.1. Selected features 
To improve the classification performance, we did feature selection for all four modalities 
(MRI, FDG-PET, CSF biomarkers and neuropsychological tests) using information gain (IG) 
method in DIAN across different EYO.  
In MRI, feature selection was applied to cortical and subcortical volumes of 82 ROIs. Most 
informative features were selected to distinguish mutation and non-mutation carriers across 
the whole EYO range. The results showed volumes of paracentral lobule and 
postcentral gyrus were selected as most important features at more than 15 years before the 
onset of symptoms. Similar regions have been found showing a difference in amyloid 
deposition between mutation and non-mutation carriers at the same EYO and became more 
significant in the following years (Benzinger et al., 2013). At the EYO = (−15,−5], the same 
brain regions paracentral lobule and postcentral gyrus, with the addition of supramarginal 
gyrus were selected for classification. By EYO = (−20,−10], selected features of grey matter 
volumes were left putamen and right lingual. Atrophy and  
¹¹C-PiB accumulation in putamen have been reported in recent ADAD research with EYO = -
10 and -15 respectively (Benzinger et al., 2013; Gordon et al., 2018). At the EYO interval (−10, 0], accumbens and precuneus were selected as the most informative features. 
Consistent to our results, the same gray matter regions were found with greatest cortical 
thinning or volume loss at the same EYO interval (Benzinger et al., 2013). From five years 
before the estimated year of onset, more features were selected including subcortical regions 
such as putamen, hippocampus, amygdala and cortical regions such as banks of the superior 
temporal sulcus, postcentral gyrus, cuneus and precuneus which were known to be vulnerable 
in AD. In ADAD, cortical thickness changes in precuneus, temporal lobe and subcortical 
regions when approaching to the year of symptom onset have been shown in the recent study 
(Gordon et al., 2018), suggesting similar patterns between most informative features for 
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distinguishing mutation vs non-mutation carriers and brain structure changes in the progress 
of ADAD.  
For FDG-PET, the most informative features were selected from SUVR scores of 82 ROIs 
across the entire EYO window. Selected features at more than 15 years before the onset of 
symptoms were shown in the caudal anterior cingulate cortex, fusiform and superior parietal 
cortex. Hypometabolism in parietal lobe has been observed in AD (Mosconi et al., 2006). But 
the other regions selected in the very early stage have not been reported previously which 
may due to the subtle difference in this stage. By EYO = (−20,−10], selected features of 
FDG-PET were hippocampus, amygdala and frontal pole. Hippocampus has been shown with 
reduction of glucose metabolism when approaching the symptom onset in ADAD (Benzinger 
et al., 2013). Our result showed that hippocampus was also selected at the next EYO interval (−15,−5] but not at the following EYO. Besides hippocampus, pallidum and accumbens of 
subcortical regions were selected at the EYO = (−15,−5] which have been shown with a 
significant difference in PiB accumulation but not in FDG-PET between mutation carriers and 
non-carriers at almost the same time in ADAD (Benzinger et al., 2013). At the EYO interval (−10, 0], inferior parietal, cuneus, and isthmus-cingulate cortex were selected as the most 
informative features. Similar regions (cingulate cortex and parietal lobe) have been shown 
with a significant difference in hypometabolism between mutation carriers and noncarriers 10 
years before symptom onset. More cortical features of FDG-PET were selected around the 
onset of symptoms including precuneus, isthmus-cingulate cortex, inferior and superior 
parietal cortex which were consistent with previous findings that these regions differ between 
carriers and non-carriers in ADAD and also showed metabolic reductions in SAD (Bateman 
et al., 2012; Förster et al., 2012; Gordon et al., 2018).  
The selected features from neuropsychological tests were relatively consistent across EYO. 
Boston Naming test was the most frequently selected feature among neuropsychological 
features which is a measure of naming ability and semantic memory and one of the most used 
 
 
67 
assessments of cognitive function in AD.  Animal Category Fluency Test is a measure of 
semantic memory and executive function which was selected multiple times especially in the 
years before symptom onset. Fluency score has been used to predict MCI conversion and 
showed good performance in the recent study (Clark et al., 2016). At the EYO interval (−15,−5] and the years after symptom onset, Trail Making Tests (A&B) were selected for 
further classification. Trail Making Test is a measure of processing speed, visual–motor skills, 
and executive functions which has been shown with a relatively good result for predicting 
MCI conversion but not for differentiating HC and AD as a single predictor (Ewers et al., 
2012). As a measure of episodic memory, Word List Recall Test was selected at ten years 
before symptom onset and at the EYO interval (−5,+5]. However, in a recent study, it has 
been shown increasing difference between mutation and non-mutation carriers (CDR = 0) in 
the progress of ADAD and it has been reported with high accuracy for the classification of 
HC and AD (Ewers et al., 2012; Storandt et al., 2014). So the Word List Recall Test was not 
selected in the late stage of ADAD which remains unclear. MMSE, a widely used test to 
evaluate cognitive impairment and screen for possible dementia, was only selected at one 
EYO interval (−10, 0]. This may suggest that the global cognitive function did not show the 
significant difference between mutation and non-mutation carrier in most time during the 
disease progress which may due to late changes are usually shown in cognitive impairment.  
Among CSF biomarkers, phosphorylated Tau was selected as the informative feature across 
all EYO intervals, which may imply a significant difference between mutation and non-
mutation carriers in the whole progress of ADAD. In recent research, concentrations of pTau 
have been shown significantly higher in mutation carriers than non-mutation carriers from 20 
years before the estimated year of symptom onset which is consistent with our result (Fagan 
et al., 2014b). As another selected feature of CSF biomarkers, Ab was selected mainly in the 
later stage of ADAD compared to pTau which was from 15 years before symptom onset 
expect the EYO interval (−5,+5]. Similarly, Ab1-42 in mutation carriers was shown a 
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significant difference from those of non-mutation carriers from 10 years before symptom 
onset (Fagan et al., 2014b). Even though Ab1-42 was selected across almost all time intervals 
from EYO = 	−15, it still remains unclear why it was not selected at the EYO interval (−5,+5] which also has been shown with a big difference between the two groups in the 
other study (Fagan et al., 2014b). Longitudinal change of Tau in SAD and difference between 
the mutation and non-mutation carriers in ADAD was reported previously (Bateman et al., 
2011). However, in our study, total Tau was not selected across the whole range EYO.  
 
4.2. Classification in DIAN 
Previous studies have shown brain atrophy, glucose hypometabolism, abnormalities in CSF 
and cognitive impairment in the progress of ADAD. So we derived features from 
neuroimaging (MRI, FDG-PET), CSF biomarkers, and neuropsychological tests. 
With the selected features, we trained the classification model for successive EYO intervals to 
predict the mutation status and the results showed increasing classification accuracy in the 
disease course. 
For machine learning model establishing, we used Naïve Bayes algorithm using the features 
of MRI, FDG-PET, neuropsychological and CSF data. Naïve Bayes algorithm has been used 
in the prediction of AD previously and it has been proved to have good performance with 
limited size of training data and relatively low dimensional feature space which is fit for our 
training dataset of DIAN (Dyrba et al., 2013; Dukart, Sambataro and Bertolino, 2015; Bhagya 
Shree and Sheshadri, 2018). In different stages of ADAD, classification model was trained 
with selected features of that EYO interval. As expected, classification accuracy increased 
with the EYO intervals approaching the symptom onset.  
Among the classifications with single modality, CSF predictors yielded the highest, and in 
opposite neuropsychological predictors showed lowest AUC from 15 years before symptom 
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onset, which is in consistency with the temporal ordering of biomarkers in ADAD where the 
earliest change was CSF biomarkers and cognitive change was shown at the late stage of 
ADAD (Bateman et al., 2012). At this EYO interval, AUC of MRI and FDG-PET measures 
were between neuropsychological test and CSF biomarkers. Previous studies reported that 
brain atrophy and hypometabolism could be detected following CSF biomarkers which could 
explain our result that CSF predictors performed better than MRI and FDG-PET in a very 
early stage of the disease. For the CSF predictors, classification result generally increased and 
better than the other single-modality models across almost all time intervals (except the EYO 
interval (−15,−5]). CSF predictors achieved a predictive accuracy from EYO interval (−10, 0] which was earlier than FDG-PET, neuropsychological assessments and MRI. In 
general, the result of the single-modality classification models showed a trend toward 
increasing AUC when the time gets closer to the symptom onset, and it is consistent with the 
model of dynamic biomarkers in ADAD proposed in recent year (Bateman et al., 2012). 
However, the measures used in our research were not exactly same as those of the temporal 
model of ADAD (e.g. gray matter volumes of multiple regions used in our study and only 
hippocampus volume used in the temporal model), so the minor difference still remains. 
For the two-modality predictors, there were 6 different combinations of MRI, FDG-PET, 
neuropsychological tests and CSF biomarkers. Comparing with single-modality predictors, 
we found that the best two-modality combinations were not always the combination of the 
best single modality which was also shown in the previous study (Dukart, Sambataro and 
Bertolino, 2015). Combining MRI and CSF biomarkers, the AUC became clinical relevant 
from the EYO interval of (−20,−10] which was earlier than every single modality predictor. 
In general, the classification result of either the best combination or averaging all six 
combinations were better than those of single modality which was shown in Table 9 and 
Figure 26. 
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For the three-modality predictors, combining MRI, FDG-PET and CSF biomarkers achieved 
the highest AUC at most EYO intervals. Generally, the average of all three-modality 
combinations was better than those of 2-modality combinations which were shown in Figure 
26. The best combination models with three modalities were better than two-modality 
combination for most EYO intervals. When the predictors with every single modality showed 
relatively high AUC especially in the late stage of ADAD, the multi-modality model may 
gain extra benefits through combination. In comparison with the best model of 3-modality 
combinations at each EYO interval, 4-modality combination model performed better only at 
the EYO interval of (−5,+5].  However, the AUC of the model combining all modalities was 
higher than the average of all three-modality combinations across all EYO intervals. In 
general, combining multiple modalities showed a gain over the model of fewer modalities for 
the discrimination between mutation and non-mutation carriers in ADAD (Figure 26).  
Mutation carriers of ADAD can be tracked decades before the symptom onset. Importantly, 
clear AD-related brain changes can be detected in the early stage of ADAD. Multi-modality 
modals to predict conversion of AD have been used in previous studies (Ewers et al., 2012; 
Segovia et al., 2014; Dukart, Sambataro and Bertolino, 2015; Korolev, Symonds and Bozoki, 
2016). All of these studies established the model based on SAD related dataset which may 
include non-AD-specific pathology for the subjects who are in the early stage of AD. Hence, 
we used the machine learning model based on pure AD-related features extracted from DIAN 
participants to predict the conversion of SAD. Before further applying the prediction model to 
ADNI dataset, we evaluated the models of different modality predictors at different EYO 
intervals in DIAN. Considering the model need to be relativity accurate and robust, we thus 
chose the prediction model trained for EYO interval of (−5, Inf) which is above the clinically 
relevant accuracy and similar to the early stage of SAD. The EYO interval of (−5, Inf) is 
combined of two intervals to enlarge the sample size and gain more power for the model. 
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For MRI, the selected features included hippocampus, putamen, amygdala, precuneus, 
postcentral gyrus, and cuneus. Difference between mutation and non-mutation carriers in the 
similar regions and timepoint in the course of ADAD was shown in the recent study where the 
significant difference was observed in postcentral gyrus , precuneus, cuneus and hippocampus 
(Gordon et al., 2018). Consistent brain regions (inferior and superior parietal cortex, 
precuneus) were also found in FDG-PET both in our and Gordon’s study. For 
neuropsychological tests, the most discriminative features were Boston Naming Test, Trail 
Making Test (A&B) and Word List Immediate Recall. For CSF biomarkers, Ab and pTau 
were selected as the most informative features. Our classification results showed the AUCs of 
all single and multiple modalities predictors were above the clinically relevant accuracy for 
distinguishing mutation and non-mutation carriers at the EYO interval of (−5,+𝐼𝑛𝑓) which 
met one of the prerequisites: an accurate predictive model. Based the classification results 
validated within DIAN dataset, the best models among different combinations were selected 
for further validation in ADNI dataset. 
 
4.3. Classification in ADNI 
Applied with the best models of the different number of modalities established in DIAN, 
classification in the more common SAD (ADNI dataset) showed high accuracy for 
distinguishing HC vs. AD and MCI converters vs. non-converters. 
For the classification of HC and AD subjects, the CSF model showed the best result among 
the single-modality models. When FDG-PET was added, the combination of CSF and FDG-
PET yielded significant a better result than the single-modality model. Compared to two-
modality model, combining MRI, FDG-PET and CSF biomarker achieved significant higher 
AUC of 96.00% (sensitivity = 93.35%, specificity = 91.40%). Similarly, a combination of 
these three modalities was reported in a previous study with an accuracy of 92.0% which was 
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significantly better than the single modality. It should be noted that the psychological data 
was not included for the classification of HC and AD, since it provided diagnostic 
information which may lead to circularity. 
For the prediction of conversion in the early stage of AD, the classification for both HC and 
MCI converters versus non-converters performed best when using neuropsychological data 
among the single predictors. This result is consistent with the previous relevant study which 
reported higher AUC using cognitive measures than MRI and CSF data to predict HC to MCI 
at 5 years (Albert et al., 2018). With multi-modalities, the classification for MCI converters 
versus non-converters in SAD showed the best result when using FDG-PET, 
neuropsychological and CSF data which increased significantly compared to single and two-
modality models with AUC of 89.16% which is above the clinical relevant accuracy. This 
result was comparable with recent studies which reported classification accuracy between 
80% to 90% for discrimination of MCI converters and non-converters combining three 
modalities (Segovia et al., 2014; Cheng et al., 2015; Dukart, Sambataro and Bertolino, 2015; 
Moradi et al., 2015; Suk, Lee and Shen, 2015; Wang et al., 2016; Tong et al., 2017). 
However, different modality combinations were used in different studies which limited the 
comparability of accuracies.  
Combination of all four modalities didn’t show a better result than three modalities, indicating 
the model didn’t gain more useful information for the prediction of MCI conversion by 
adding MRI features. Combination of different modalities didn’t benefit for HC converters 
versus non-converters where none of the multi-modalities performed better than the single 
modality of neuropsychological data. There were very few studies in recent years predicted 
the conversion of healthy subjects which may due to limited of follow-up for HC and thus the 
sample size (the number of subjects who developed to MCI/AD) was not sufficient for 
prediction. In our study, there was only 14 HC subjects who converted within 36 months and 
the limited the sample size may lead to lacking robustness. There was one recent study 
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reported relatively high AUC for predicting progression from HC to MCI at 5 years based 
on the Cox proportional hazards model. However, with machine learning algorithms, there 
was no study showing the prediction of HC conversion so far (Pellegrini et al., 2018). 
Though many previous studies used multi-modality machine learning models for the 
prediction in the early stage of AD in previous studies, most studies tested the prediction 
model using the cross-validation method. This means training and testing data were not 
independent and it may increase the risk of overfitting. Our current study used fully 
independent training (DIAN dataset) and testing set (ADNI dataset). Even though ADAD 
only accounts for a small proportion of AD, because of similar pathological and clinical 
features, it has a critical role to better understand the pathophysiology in the preclinical stage 
of SAD. 
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5 Conclusion 
 
With the use of neuroimaging, psychological and CSF biomarkers, we did classification for 
successive EYO intervals to predict the mutation status and the results showed increasing 
classification accuracy in the disease course for both single modality and multi-modality 
models. Considering the model need to be relativity accurate and robust, we thus chose the 
prediction model trained for EYO interval of (−5, Inf) which is above the clinically relevant 
accuracy and similar to the early stage of SAD.  
Applied with the best models established in DIAN, classification in the more common SAD 
(ADNI dataset) showed high accuracy for distinguishing HC vs. AD and MCI converters vs. 
non-converters. Combining multiple modalities, the prediction model yielded a significant 
better result than the single-modality model. Particularly, the classification for MCI 
converters versus non-converters in SAD showed the best result when using FDG-PET, 
neuropsychological and CSF data which increased significantly compared to single and two-
modality models with AUC of 89.12% which is above the clinical relevant accuracy. In 
summary, the machine learning model established in DIAN achieved predictive accuracy to 
predict the conversion in the early stage of SAD. Moreover, the current study provides good 
interpretability to understand SAD through autosomal-dominant AD.  
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6 Supplement 
 
 
 
Figure 25 (A) 3D scatter plot of CSF data for the group comparison (ADNI vs DIAN) (A) before and (B) 
after normalization and standardization.  
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Figure 26 Mean AUC for the discrimination of mutation carriers vs. non-mutation carriers of single 
modality, two-modality combination, three-modality and all combination across different EYO intervals.  
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